

08/982-402



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : A61K 37/50, C07K 3/04, 3/02 C07K 7/10, 13/00, C12Q 1/28 G01N 33/564, 33/573</p>	<p>A1</p>	<p>(11) International Publication Number: WO 93/23073 (43) International Publication Date: 25 November 1993 (25.11.93)</p>
<p>(21) International Application Number: PCT/US93/03837 (22) International Filing Date: 22 April 1993 (22.04.93) (30) Priority data: 07/885,656 19 May 1992 (19.05.92) US (60) Parent Application or Grant (63) Related by Continuation US 07/885,656 (CIP) Filed on 19 May 1992 (19.05.92) (71) Applicant (for all designated States except US): THE RE- GENTS OF THE UNIVERSITY OF MICHIGAN [US/ US]; 475 E. Jefferson, Room 2354, Ann Arbor, MI 48109-1248 (US).</p>	<p>(72) Inventors; and (75) Inventors/Applicants (for US only): BAKER, James, R., Jr. [US/US]; 3997 Holdon Drive, Ann Arbor, MI 48103 (US). KOENIG, Ronald, J. [US/US]; 1215 Wynnstone, Ann Arbor, MI 48105 (US). (74) Agents: LEWAK, Anna, M. et al.; Harness, Dickey & Pierce, P.O. Box 828, Bloomfield Hills, MI 48303 (US). (81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report.</p>	
<p>(54) Title: THYROID PEROXIDASE EPITOPIC REGIONS</p> <p>(57) Abstract</p> <p>Specific eptitopic regions of thyroid peroxidase (TPO), a thyroid-specific membrane autoantigen, have been identified from amino acid 456 to 933, with distinct epitopic regions from amino acid 517 to 630 and from 633 to 933 of the TPO molecule, the former region having at least one distinct binding region therewithin located from aminoacid 592 to 613. The identification and production of these localized epitopes/epitopic regions provide specific diagnostic reagents for autoimmune thyroid disease. As a thyroid-specific immunogenic structure, the TPO epitope/epitopic regions identified can be used for immunotherapy of thyroid disease and thyroid cancer.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

- 1 -

THYROID PEROXIDASE EPITOPIC REGIONS RELATED APPLICATIONS

This is a continuation-in-part of U.S. Application Serial No. 07/885,656, entitled "Thyroid Peroxidase Epitopic Regions," filed May 19, 1992, herein incorporated by
5 reference.

GENBANK INFORMATION

Thyroid peroxidase sequence has been previously accorded GenBank Accession No. J02969.

FIELD OF THE INVENTION

10 The present invention relates generally to thyroid peroxidase and, more specifically, to autoantibody epitopic regions of thyroid peroxidase and diagnostic and therapeutic applications thereof.

BACKGROUND OF THE INVENTION

Thyroid peroxidase (TPO) is the major thyroid-specific membrane autoantigen
15 implicated in Hashimoto's thyroiditis, an autoimmune disease characterized by intense lymphocytic thyroiditis resulting in the destruction of the thyroid. Weetman, A.P. et al, *Endocrinol. Rev.* 5:309-355 (1984). TPO's role in autoimmune disease and the precise localization of autoantibody binding has, however, been a subject of much debate. For example, there has been controversy as to whether autoantibodies inhibit thyroid
20 peroxidase activity, thereby contributing to thyroid dysfunction in autoimmune thyroid disease. See Yokoyama, N. et al., *J. Clin. Endocrinol. Metab.* 68:766-773 (1989); Saller, B. et al., *J. Clin. Endocrinol. Metab.* 72:188-195 (1991). Reports on variations in the structure of TPO have suggested alternative mRNA splicing as a source of antigenicity. Kimura, S. et al., *PNAS (USA)* 84:5555-5559 (1987); Nagayama, Y. et al.,
25 *J. Clin. Endocrinol. Metab.* 71:384-390 (1990); Zanelli, E. et al., *Biochem. Biophys. Res. Commun.* 170:735-741 (1990). The appearance of these alternative transcripts in normal thyroid glands has, however, brought the relationship of alternative splicing and autoimmunity into question. Elisei, R. et al., *J. Clin. Endocrinol. Metab.*, 72:700-702 (1991). It also now appears that carbohydrate structures are not involved in TPO
30 antigenicity. Foti, D. et al., *Endocrinol.* 126:2983-2988 (1990).

Recent reports on the number and type of autoantibody epitopes found in human TPO have been conflicting. One group has suggested that TPO autoantibodies bind only to conformation epitopes and that no localized epitopes exist. Finke, R. et al., *J. Clin. Endocrinol. Metab.* 71:53-59 (1990). Given that this
35 group demonstrated binding to recombinant TPO produced in CHO cells, but was

- 2 -

unable to show binding to whole recombinant TPO in the bacterial expression system employed, the failure to identify localized epitopes could have resulted from a problem with the expression of intact TPO in bacteria. In contrast, another group has reported the identification of localized autoantibody of TPO epitopes using *in vitro* translated TPO cDNA clones. Libert, F. et al., *EMBO J.* 6:4193-4196 (1987); Ludgate, M. et al., *J. Clin. Endocrinol. Metab.* 68:1091-1096 (1989). Using sera from Hashimoto's disease patients, localized autoantibody binding was identified between amino acids 590 and 675 of the TPO coding sequence. *Id.* While initially identifying only a single antibody binding site in this region, more recent publications of this group indicated the presence of multiple antibody binding sites in the carboxyl half of the TPO molecule. Elisei, R. et al., *Autoimmunity* 8:65-70 (1990); Libert, F. et al., *J. Clin. Endocrinol. Metab.* 73:857-860 (1991). Several other studies using trypsin digests of purified native TPO have also suggested the presence of multiple autoantibody epitopes, including some which appear to be conformational and require disulfide bonds. Nakajima, Y. et al., *Mol. Cell Endocrinol.* 53:15-23 (1987); Yokoyama, N. et al., *J. Clin. Endocrinol. Metab.* 70:758-765 (1990). However, there has been no consensus on the exact number and type of epitopes present in TPO.

The identification of autoantibody thyroid-specific epitopes is important to the understanding and diagnosis of autoimmune thyroid disease and in developing effective immunotherapeutic strategies against thyroid disease and cancer. The identification of specific localized TPO epitopic regions would provide a powerful diagnostic tool for autoimmune diseases such as Hashimoto's to distinguish it from other thyroid conditions. The identification and ability to produce sequences encompassing specific TPO autoantibody epitopes would also be instrumental in developing immunotherapeutic strategies against autoimmune thyroid disease and thyroid cancer.

The development of new therapeutic approaches to treating thyroid cancer is of particular importance. Thyroid cancer is diagnosed in 10,000 individuals in the United States each year. Mazzaferri, E.L. "Thyroid Cancer," Ch. 43:319-331 (Becker, K.L. ed.) *Principles and Practice of Endocrinology and Metabolism*, J.B. Lippencott (Philadelphia PA 1990); Cooper, D.S. et al., *Endocrinol. Metab. Clin. North Am.* 19(3):577-591 (1990). While modern techniques have led to early diagnosis and treatment, approximately 10% of thyroid cancer patients develop terminal metastatic disease. Robbins, J. et al., *Ann. Intern. Med.* 115(2):133-147 (1991). Thyroid cancer presents an important public health problem in that it most commonly occurs in otherwise

- 3 -

healthy and productive individuals in the third and fourth decades of life. Mazzaferri, E.L. "Thyroid Cancer," Ch. 43:319-331 (Becker, K.L. ed.) *Principles and Practice of Endocrinology and Metabolism*, J.B. Lippencott (Philadelphia PA 1990). It is also an extremely important health problem for women, as it occurs three times as often in
5 women than in men. Kramer, J.B. et al., *Adv. Surg.* 22:195-224 (1989). The disease can also be seen in children, especially after radiation exposure. Barnes, N.D., *Horm. Res.* 30:84-89 (1989). While less common in the elderly, thyroid cancer has a much worse prognosis in this population. Mazzaferri, "Thyroid Cancer," Ch. 43:319-313 (Becker K.L., ed.) *Principles and Practice of Endocrinology and Metabolism* (J.B.
10 Lippencott, Philadelphia PA 1990); Cooper, D.S. et al., *Endocrinol. Metab. Clin. North Am.* 19(3):577-591 (1990).

Current therapeutic approaches for the two most prevalent types of thyroid cancer, papillary and follicular carcinoma, involve partial or complete thyroidectomy, often in conjunction with radioactive iodine therapy. However, a substantial number
15 of patients show no response to conventional treatment. For example, some thyroid tumors do not respond to radioactive iodine treatment because the carcinoma is not sufficiently differentiated to concentrate lethal quantities of radioactivity. Additionally, the side effects attending conventional chemotherapeutic and radiation therapy have a serious adverse impact on patient health and well-being.

20 More sensitive diagnostic and alternative therapeutic strategies against thyroid disease and cancer would thus be desirable. Such strategies can be provided with the identification of specific thyroid peroxidase epitopic regions.

SUMMARY OF THE INVENTION

Specific epitopic regions of thyroid peroxidase (TPO), a thyroid-specific cell
25 membrane enzyme and the autoantibody target in autoimmune thyroid disease, have been identified. The epitopic regions reside from amino acid 456 to 933, with two distinct regions located from amino acid 517 to 630 and from amino acid 633 to 933, the former region having at least one distinct binding region therewithin located from amino acid 592 to 613 inclusive. The latter region also has at least two distinct
30 binding regions therewithin, located from amino acid 633 to 768 and from amino acid 768 to 933. The specific epitopic regions provide a sensitive diagnostic reagent for autoimmune thyroid disease and, as thyroid-specific structures, can be used for immunotherapy of thyroid disease and cancer. Nucleic acid sequences coding for TPO epitopic regions, and sequences complementary thereto, are also contemplated
35 as being within the scope of the present invention.

- 4 -

Since TPO is expressed in most thyroid cancers, patients can be immunized with TPO epitope contained within these regions to induce or augment the immune response to TPO, specifically targeting the TPO-bearing cancer cells. Adoptive immunotherapy involving the harvesting of immune cells from the thyroid, their *in vitro* stimulation by TPO epitope and reimplantation into the patient is also now feasible. Monoclonal antibodies specific for TPO epitope/epitopic region can also be administered for passive immunotherapy.

Autoimmune thyroid disease, such as Hashimoto's thyroiditis, can also be treated by blocking or competing with autoantibody binding to native TPO in the thyroid. More sensitive assays utilizing TPO epitopic binding to screen for the presence of autoantibody are also useful in diagnosing patients with Hashimoto's disease and in distinguishing Hashimoto's from other thyroid disorders.

Other features and advantages of the present invention will become apparent from the following description and appended claims, taken in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 presents immunoprecipitation studies of recombinant thyroid peroxidase (TPO) fragments produced from different length cDNA templates.

Figure 2 summarizes immunoprecipitation results from multiple fragments (TPO constructs) of human TPO.

Figure 3 is a Western blot analysis of the production of immunoreactive recombinant TPO using the pET 3d expression vector.

Figure 4 is a Western blot analysis of MBP-TPO (AA 456-933) fusion proteins isolated from bacterial lysates by amylose affinity chromatography.

Figure 5 illustrates TPO-maltose binding protein products.

Figure 6 is a Western blot analysis of the ability of native TPO to inhibit autoantibody binding to recombinant MBP-TPO fusion protein.

Figure 7 is a Western blot analysis of thyroiditis patient sera reactivity with two different TPO epitopes.

Figure 8 is a block graph illustrating inhibition of Hashimoto's patient sera binding to native TPO in an ELISA by preincubation with different MBP fusion proteins.

Figures 9A and 9B are Western blot analyses of sera from patients with thyroiditis.

Figure 10 is a Western blot analysis of sera from patients with thyroid cancer and thyroiditis.

- 5 -

Figure 11 is an immunoblot analysis of the separation of MBP-TPO fusion proteins by preparative SDS-PAGE.

Figure 12 is a bar graph depicting autoimmune thyroiditis patient T cell proliferation in response to recombinant TPO fragments.

5 Figures 13A and B are bar graphs depicting proliferation of thyroid cancer patient peripheral blood lymphocytes (PBL) to thyroid antigens.

Figure 14 is a bar graph depicting stimulation of papillary thyroid cancer-infiltrating lymphocytes (CIL) with TPO fusion proteins.

Figure 15 is a Western blot analysis of sera from mice immunized with MBP-
10 TPO (AA 632-933).

Figure 16 is a bar graph showing the proliferation of splenocytes from a mouse immunized with MBP-TPO (AA 632-933).

Figures 17A and 17B are representative Western blots demonstrating autoantibody reactivity to recombinant TPO (AA 513-633).

15 Figure 18 is a schematic of fine mapping of a TPO epitope using PCR.

Figure 19 is a graphical representation of an ELISA immunoassay for TPO autoantibody epitopes.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS IDENTIFICATION OF TPO EPITOPIC REGIONS

20 As detailed in Specific Example I, several distinct and localized areas of thyroid peroxidase (TPO) have been found to bind autoantibodies of patients with Hashimoto's disease. These autoantibody binding regions were localized from the TPO molecule's C-terminus (AA 933) to amino acid 455, and were recognized by over 90% of the Hashimoto's patients tested. At least one autoantibody epitopic region
25 was located from amino acid 456 to 631, more specifically from amino acid 517 to 630, and another was located from amino acid 633 to 933, the former region having at least one distinct binding region therewithin located from amino acid 592 to 613. (See Specific Example V) Further studies indicated that the latter region also included at least two binding or epitopic regions from amino acid 633 to 768 and from amino
30 acid 768 to 933. The absence of local autoantibody binding in the first 455 amino acids of TPO is remarkable, although the possibility that autoantibodies bind to conformational determinants in TPO involving areas both N-terminal and C-terminal to amino acid 456 cannot be excluded.

Despite difficulties in expressing full-length TPO in *E. coli*, the results of the
35 immunoprecipitation studies described below permitted focusing on the C-terminal half

- 6 -

of this antigen. It was postulated that, due to its smaller size, a construct encoding the C-terminal half of TPO would be more likely to be successfully expressed in bacteria. To further optimize expression, an expression system with a vector (pMAL, New England BioLabs) not previously used in thyroid peroxidase studies was used to produce a bacterial fusion protein, maltose binding protein (MBP). The construct MBP-TPO (AA 456-933) was able to produce full-length fusion protein and many smaller MBP fusion proteins were also produced. The expression of the smaller C-terminal truncated fusion proteins supplemented the Western blot analysis, since the shorter fragments potentially contained fewer autoantibody recognition sites. This appeared to be the case, since some of the smaller fragments reacted with only a subset of the Hashimoto's sera. These results provided evidence that multiple epitopes are present in TPO, and that patients' sera differ in their reactivity to these epitopes.

Several fragments of human TPO recognized by human autoantibodies from a majority of Hashimoto's patients were thus identified. As noted above, these fragments were located in the carboxyl half of the molecule, after amino acid 455, and were recognized in recombinant TPO proteins. At least one autoantibody epitope was located in the region from amino acid 517 to 630, and at least two additional areas of binding were identified within the region from amino acid 633 to 933, more specifically from amino acid 633 to 768 and from amino acid 768 to 933, the former region having at least one distinct binding region therewithin located from amino acid 592 to 613. Autoantibody binding to native TPO could be competitively inhibited by preincubation with these fragments and it appeared there was heterogeneity in the fragments recognized by different Hashimoto's patients.

The TPO fragments recognized by the sera of Hashimoto's patients appear localized to the regions encoded by exons 8, 9, 10, and possibly 11. Banga, J.P. et al., *FEBS Lett.* 266:133-141 (1990). This region has homology with the cytochrome oxidase gene and is potentially involved in TPO enzymatic activity, specifically the distal heme-iron binding region. Kimura, S. et al., *Genet.* 3:113-120 (1988). This suggests a potential relationship between autoantibody binding and TPO function. The TPO fragment where autoantibody binding is localized is also a region where alternative RNA splicing reportedly results in an internal deletion of amino acids 533 to 589. Kimura S. et al., *PNAS (USA)* 84:5555-5559 (1987). The significance of this is not evident, however, as other investigators have found alternative splicing to occur only in regions of the TPO molecule not related to the epitopes identified by the

- 7 -

studies below. Nagayama, Y et al., *J. Clin. Endocrinol. Metab.* 71:384-390 (1990); Zanelli, E. et al., *Biochem. Biophys. Res. Commun.* 170:735-741 (1990). Moreover, since both of the alternative transcripts previously described also appear to be present in normal thyroid glands, the relationship of alternative splicing to the development of autoimmunity is somewhat questionable. Elisei, R. et al., *J. Clin. Endocrinol. Metab.* 72:700-702 (1991).

IMMUNODIAGNOSTIC APPLICATIONS

Immunoassays utilizing isolated natural epitope, the recombinant protein, or a synthetic peptide representing specific TPO epitopic regions can be used to evaluate patients for autoimmune thyroid disease. By screening for antibodies against the TPO epitope or epitopic region, patients with autoimmune thyroid disease such as Hashimoto's can be distinguished from patients with other thyroid disorders, such as Graves' disease.

Current immunoassays for diagnosing Hashimoto's disease use whole thyroid microsomal antigen partially purified from bovine thyroid glands. While this material contains TPO, it is also contaminated with many other bovine proteins and has a slightly different structure from the human antigen. Possibly as a result of such contamination and species dissimilarities, current assays are only about 80% sensitive and do not correlate well with disease activity.

The present invention provides substantially pure TPO epitopic sequences which can be consistently produced in large quantities. As used with respect to the present invention described in the specification and claims, the term "TPO epitopic region, sequence, peptide or amino acid" is meant to include a region or sequence of TPO from amino acid 456 to 933 of SEQ ID NO. 1 or fragment thereof which includes at least one distinct TPO epitope, unless otherwise indicated or evident from the use of the term in context. It will be appreciated that this term thus also includes simply TPO epitope. The term should also be construed broadly as to the source of the TPO epitope or region, whether isolated from natural or recombinant sources or synthetically produced, unless otherwise indicated or evident from the context in which the term is used. By "substantially pure TPO epitopic region, sequence, peptide or amino acid" is meant TPO epitopic region or sequence from any of these sources which is substantially free from undesirable contaminants such as other proteins, with a purity of greater than 90%. The term is not meant to exclude TPO epitope or region which is linked, bound to or intentionally combined with other moieties such as carrier proteins, labels, flanking amino acid sequences and the like. Nucleic acid sequences,

- 8 -

either DNA or RNA, consisting essentially of the coding sequences for the TPO epitopic regions or fragments thereof described above, and nucleic acid sequences complementary thereto, are also contemplated as within the scope of the present invention.

5 TPO epitopes encompassed by the present invention are specific for thyroid peroxidase and, in substantially pure form, show no measurable cross-reactivity with other types of peroxidase enzymes as seen with whole molecule immunoassays currently in use. The use of TPO epitope as an immunodiagnostic tool in accordance with the present invention thus has the distinct advantage that it is recognized only
10 by antibodies against the specific binding site in human TPO, the actual autoantigen associated with the disease. Furthermore, recombinant or synthetic epitopic regions can be produced in homogenous or substantially pure form without contaminating animal proteins.

As described above and detailed in Specific Example I, the identification of
15 specific TPO epitopic regions and the development of an exemplifying immunodiagnostic assay involved several steps. Prior to this work it was believed that TPO needed to be intact in order to be recognized by antibodies. Using a eukaryotic expression system, it was found that large portions of the TPO coding region could be removed without destroying the antigenic activity. As discussed in Specific
20 Example I, a small segment of the TPO gene coding for approximately 180 of the 933 amino acids in the whole molecule was identified which seemed to identify the antigenic epitope. In order to produce large amounts of this protein for investigation, an expression system using a vector not previously employed in TPO studies was able to translate this specific segment of the molecule. By inserting a small segment of the
25 TPO gene into an appropriate vector, an approximately 140 amino acid fragment of TPO fused to a carrier protein was produced. This fusion protein (MBP-TPO) reacted with human Hashimoto's sera but not with control sera, and inhibited binding to larger portions of the molecule. By using this unique expression system, a recombinant autoantibody epitope was identified and produced.

30 The further localization of the TPO epitope to a 140 amino acid region between amino acids 517 and 633 results in the ability to produce substantially pure natural or recombinant TPO epitopic sequences or synthetic peptides corresponding to or containing a TPO epitopic region. The specific TPO epitopes of the invention can be used in a variety of immunobinding assay schemes known to those skilled in the art
35 to detect the presence of antibody in clinical or research settings. As described in

- 12 -

therapeutically effective amount of the epitope will be administered for a therapeutically effective duration. By "therapeutically effective amount" and "therapeutically effective duration" is meant an amount and duration to achieve a selected desired result in accordance with the present invention without undue adverse physiological effects, which can be determined by those skilled in the medical arts. It will also be appreciated that administration of the epitopic regions and reagents and vaccines which include the epitopes of the present invention, will be by procedures well established in the pharmaceutical arts, e.g. intramuscular, subcutaneous, intradermal and oral administration, either alone or in combination.

10 **Thyroid Cancer.** Although there are four types of thyroid carcinomas, medullary, anaplastic, papillary and follicular, the latter two cell types which both arise from the thyroid follicular cells, account for 85% of all thyroid cancers. Papillary cancer accounts for approximately 70% of all thyroid cancers and 85% of radiation-induced cancers. Mazzaferri, E.L., "Thyroid Cancer," Ch. 43:319-331 (Becker, K.L. ed.) *Principles and Practice of Endocrinology and Metabolism*, J.B. Lippencott (Philadelphia, PA 1990); Cooper, D.S. et al., *Endocrinol. Metab. Clin. North Am.* 19(3):577-591 (1990). Follicular cancer accounts for 15% of all thyroid cancers, and is seen more commonly in the elderly and in patients with goiter from iodine deficient areas. Block, B.L. et al., *Otolaryngol. Clin. North Am.* 23(3):403-411 (1990). Follicular cancer can manifest an aggressive nature despite a benign pathologic appearance, and is more likely than papillary cancer to be metastatic when first diagnosed. Block, B.L. et al., *Otolaryngol. Clin. North Am.* 23(3):403-411 (1990); Watne, A.L. et al., *Semin. Surg. Oncol.* 7(2):87-91 (1991). The overall 10-year mortality of 15 to 50% in patients diagnosed with follicular cancer reflects both the more aggressive nature of this tumor and the poor course seen in elderly individuals with this tumor. Watne, A.L. et al., *Semin. Surg. Oncol.* 7(2):87-91 (1991). In either papillary and follicular carcinomas, larger tumors (>3-5 cm) are associated with poorer outcomes. Watne, A.L. et al., *Semin. Surg. Oncol.* 7(2):87-91 (1991). Smaller lesions can follow a benign and protracted course, but are also found in association with distant metastasis.

30 Mazzaferri, E.L., "Thyroid Cancer," Ch. 43:319-331 (Becker, K.L. ed.) *Principles and Practice of Endocrinology and Metabolism*, J.B. Lippencott (Philadelphia, PA 1990); Cooper, D.S. et al., *Endocrinol. Metab. Clin. North, Am.* 19(3):577-591 (1990). Thyroid cancers are present *in situ* in approximately 10% of all autopsy specimens, indicating that a benign pre-clinical form of the disease is very common. Bisi, H. et al., *Cancer*

64(9):1888-1893 (1989); Clark, O.H. et al., *Eur. J. Cancer Clin. Oncol.* 24(2):305-313 (1988).

It is important to note that papillary and follicular thyroid carcinoma maintain many of the characteristics of follicular thyroid cells. They display specific proteins associated with thyroid cells, such as the TSH receptor, thyroglobulin and TPO. Mazzaferri, E.L., *J. Clin. Endocrinol. Metab.* 70(4):826-829 (1990); Paul, S.J. et al., *Endocrinol. Metab. Clin. North Am.* 19(3):593-612 (1990). They also function in a manner consistent with thyroid cells, responding to TSH stimulation, concentrating iodine and producing thyroglobulin and thyroid hormone. These features have important implications for treatment and also aid in diagnosis. Tumors that concentrate iodine can be identified and located with ^{123}I or ^{131}I scans, and recurrences of tumors after resection or treatment can be detected by monitoring serum levels of thyroglobulin or by radioactive scanning. Krenning, E.P. et al., *Eur. J. Cancer Clin. Oncol.* 24(2):299-304 (1988); Sisson, J.C., *Endocrinol. Metab. Clin. North Am.* 18(2):359-387 (1989).

Current Therapy for Thyroid Cancer. Papillary carcinoma is often cured by partial or complete thyroidectomy with thyroid hormone replacement therapy to suppress endogenous TSH stimulation of the cancer when the lesion is small (less than 1.5 cm) and well circumscribed. Mazzaferri, E.L., *Semin. Oncol.* 14(3):315-332 (1987). However, in patients over 40 years of age, patients with a history of radiation exposure, patients with multifocal tumors and patients with local lymphatic metastasis, thyroidectomy alone is associated with up to a 40 to 60% recurrence rate in patients with a primary tumor greater than 2.5-3.0 cm. Khan, A. et al., *Throat J.* 68(1):31-32, 34, 39-40 (1989). In these cases and in patients initially presenting with distant metastasis, surgery is followed by adjunctive therapy with radiiodine. Mazzaferri, E.L., "Thyroid Cancer," Ch. 43:319-331 (Becker K.L., ed.) *Principles and Practice of Endocrinology and Metabolism*, J.B. Lippencott (Philadelphia PA 1990); Cooper, D.S. et al., *Endocrinol. Metab. Clin. North Am.* 19(3):577-591 (1990). While retrospective studies suggest this decreases recurrence rates in many patients, especially in the absence of metastatic disease, some patients have only partial responses to radiiodine and receive a maximal cumulative dose of 800-1000 mCi of ^{131}I without achieving a complete remission. In addition, many metastasis do not concentrate iodine and show no response to ^{131}I administration. This results in a substantial portion of patients (10 to 20%) with papillary cancer who can not be cured by traditional therapy. The overall outlook for these patients is bleak, as no

- 14 -

chemotherapeutic regiment or other treatment modality has been shown to be effective. Knols, L.K. et al., *Semin. Oncol.* 14(3):343-353 (1987). This results in a 10-20% cancer-related mortality for papillary cancer patients in the 20 years following diagnosis. Mazzaferri, E.L., "Thyroid Cancer," Ch. 43:319-331 (Becker, K.L. ed.)

5 *Principles and Practice of Endocrinology and Metabolism*, J.B. Lippencott (Philadelphia, PA 1990); Cooper, D.S. et al. *Endocrinol. Metab. Clin. North Am.* 19(3):577-591 (1990).

Follicular thyroid cancer shares many of the same treatment concerns as papillary cancer, however it is even more lethal. Watne, A.L. et al., *Semin. Surg.*

10 *Oncol.* 7(2):87-91 (1991). Total thyroidectomy for follicular carcinoma without radioiodine therapy does not commonly yield a cure because of the cancer's propensity to widely metastasize. Cooper, D.S. et al., *Endocrinol. Metab. Clin. North Am.* 19(3):577-591 (1990). Patients with metastases that do not concentrate iodine tend to have particularly unfavorable outcomes because this tumor is usually more

15 aggressive than its papillary counterpart. Chemotherapy for follicular cancer is also ineffective, and patients often require additional surgery or local radiation for palliation. In older patients with invasive disease, follicular cancer results in mortality rates of 50% in the ten years following diagnosis. Watne, A.L. et al., *Semin. Surg. Oncol.* 7(2):87-91 (1991).

20 Thus, while current therapy for thyroid cancer may be effective, a substantial proportion of patients do not respond to these measures. In these patients, there are currently no alternative therapeutic modalities to relieve their substantial morbidity and mortality. The many patients with thyroid cancer who respond well to conventional treatment obscure the serious nature of this disorder in those patients with

25 progressive disease.

Immune Aspects of Thyroid Cancer. Several findings suggest the immune system attempts to regulate neoplastic thyroid cells. For example, the presence of thyroid cancers *in situ* in 10% of autopsies suggests that neoplastic transformation of thyroid cells is relatively common. Bisi, H. et al., *Cancer* 64(9):1888-1893 (1989); Clark,

30 O.H. et al., *Eur. J. Cancer Clin. Oncol.* 24(2):305-313 (1988). It is possible that a secondary neoplastic event or possibly the breakdown of immune surveillance results in a clinically recognizable thyroid cancer. There is often a lymphocytic infiltrate surrounding papillary thyroid cancer, and this infiltrate can become so intense it must be differentiated from autoimmune thyroiditis. Mazzaferri, E.L., "Thyroid Cancer," Ch.

35 43:319-331 (Becker K.L., ed.) *Principles and Practice of Endocrinology and*

Metabolism, J.B. Lippencott (Philadelphia PA 1990); Cooper, D.S. et al., *Endocrinol. Metab. Clin. North Am.* 19(3):577-591 (1990). In contrast to papillary cancer, follicular cancer does not commonly induce a local immune response (Watne, A.L. et al., *Semin. Surg. Oncol.* 7(2):87-91 (1991)) which may relate to the propensity for this cancer to metastasize. The fact that thyroid cancer is also more progressive and more likely to metastasize in elderly patients (Mazzaferri, E.L., "Thyroid Cancer," Ch. 43:319-331 (Becker, K.L. ed.) *Principles and Practice of Endocrinology and Metabolism*, J.B. Lippencott (Philadelphia PA 1990)) may also be a reflection of decreased immune function in this population.

- 10 In addition to the local histologic changes, patients with thyroid cancer often have antithyroid antibodies, including serum antibodies against thyroglobulin and thyroid peroxidase. Mazzaferri, E.L., Thyroid Cancer, Ch. 43:319-331 (Becker K.L. ed.) *Principles and Practice of Endocrinology and Metabolism*, J.B. Lippencott (Philadelphia PA 1990); Cooper, D.S. et al., *Endocrinol. Metab. Clin. North Am.* 19(3):577-591 (1990).
- 15 Antibodies against these antigens do not seem to alter the prognosis or progression of the cancer and patients with antibodies against the either TPO or thyroglobulin are just as likely as patients without antibodies to die from their tumor. Pacini, F. et al., *Acta. Endocrinol.* (Copenh.) 119(3):373-80 (1988). Antibodies against the TSH receptor are also reported to occur in patients with thyroid cancer. Filetti, S. et al., *N. Engl. J. Med.* 318(12):753-759 (1988). This type of immune response may be detrimental, as anti-TSH receptor antibodies have been reported to cause tumor stimulation in some thyroid cancer patients. Belfiore, A. et al., *J. Clin. Endocrinol. Metab.* 70(4):830-835 (1990). However, the demonstration of antithyroid antibodies in thyroid cancer patients suggests that these patients are able to mount immune
- 20 responses to a variety of thyroid-associated antigens.

- Because serologic immunity is ineffective in many neoplasms and has not appeared helpful in controlling thyroid cancer, cellular immunity might be necessary to suppress thyroid neoplasms. In these patients the induction of antithyroid antibodies require a cellular immune response, and cellular cytotoxic immune
- 30 responses are reported in tumor infiltrating lymphocytes (TIL) isolated from thyroid cancer. Bagnasco, M. et al., *J. Clin. Endocrinol. Metab.* 69(4):832-836 (1989). However, the cellular cytotoxic activity of these TIL is not increased compared to the levels seen in peripheral blood and the predominant cytotoxic activity in the thyroid is due to NK cells not directed specifically towards thyroid cells. Bagnasco, M. et al.,
- 35 *J. Clin. Endocrinol. Metab.* 69(4):832-836 (1989). Importantly, papillary cancer TIL

- express lower levels of activation markers than intrathyroidal lymphocytes from patients with thyroiditis. Bagnasco, M. et al., *J. Clin. Endocrinol. Metab.* 69(4):832-836 (1989); Bagnasco, M. et al., *Clin. Exp. Immunol.* 83(2):309-313 (1991). The thyroid cancer cells themselves do not express ICAM1 and have decreased expression of
- 5 Class I HLA antigens, indicating a local absence of cytokines (such as γ interferon and $\text{TNF}\alpha$) produced by activated mononuclear cells. Bagnasco, M. et al., *Clin. Exp. Immunol.* 83(2):309-313 (1991); Liaw, K.Y. et al., *Cancer* 46(2):285-288 (1980). Several defects in cytotoxic immune responses have also been documented in the peripheral blood mononuclear cells from patients with papillary cancer, including decreased
- 10 blastogenic responses to mitogens and additional work has shown a specific defect in peripheral blood NK lysis of thyroid cancer cells. Aoki, N. et al., *Clin. Exp. Immunol.* 38(3):523-530 (1987); Boros, P. et al., *Haematologia* (Budap.) 20(3):189-193 (1987); and Sack, J. et al., *Cancer* 59(11):1914-1917 (1987). Proliferative responses to thyroid antigens are also not as intense in cancer patients as in patients with thyroiditis and
- 15 are seen in a much smaller percentage of cancer patients. Bagnasco, M. et al., *J. Clin. Endocrinol. Metab.* 69(4):832-836 (1989). Additionally, non-specific immune stimulation at the time of thyroidectomy has been shown to decrease papillary cancer recurrence rates. Durie, B. G. et al., *Cancer Clin. Trials* 4(1):67-73 (1981). Particular HLA alleles and IgG allotypes (Gm) are associated with the development of thyroid
- 20 cancer, reinforcing the concept of an immune defect in these patients. (Juhasz, F. et al., *Cancer* 63(7):1318-1326 (1989); Juhasz, F. et al., *Clin. Endocrinol. (Oxf.)* 25(1):17-21 (1986). Thus, while there is evidence of a primary cytotoxic immune response to thyroid cells in thyroid cancer patients, it appears inadequate to control the neoplastic cells.
- 25 **Chronic Thyroiditis: Cellular Immunotherapy of Thyroid Cancer.** The augmentation of cellular immune responses to control thyroid cancer is supported by Hashimoto's (autoimmune) thyroiditis. As discussed previously, this disorder is caused by a specific immune response to thyroid antigens that results in an intense lymphocytic thyroiditis. Weetman, A.P. et al., *Endocrinol. Rev.* 5(2):309-355 (1984).
- 30 While Hashimoto's is associated with thyroid-specific B cell immune responses, as demonstrated by antibodies to TPO and thyroglobulin (Weetman, A.P. et al., *Endocrinol. Rev.* 5(2):309-355 (1984)), a predominance of thyrocyte-specific T cell responses are observed. Weetman, A.P. et al., *Endocrinol. Rev.* 5(2):309-355 (1984). Importantly, the majority of T cell clones isolated from intrathyroidal cells are CD8^+
- 35 phenotype and demonstrate cytotoxic activity against thyroid cells, with the end result

usually being hypothyroidism from the complete destruction of the thyroid gland. Bagnasco, M. et al., *J. Clin. Endocrinol. Metab.* 69(4):832-836 (1989); MacKenzie, W.A. et al., *J. Clin. Endocrinol. Metab.* 64(4):818-824 (1987). The histologic appearance of thyroid glands from patients with end stage thyroiditis demonstrates mainly lymphocytic immune elements and fibrosis. Few, if any, thyroid cells are present and there is total disruption of the normal thyroid architecture. Weetman, A.P. et al., *Endocrinol. Rev.* 5(2):309-355 (1984).

Animal models of thyroiditis reinforce the central role of cellular immunity in the pathogenesis of this disorder. Thyroiditis can be passively transferred between animals by T lymphocytes, T lymphoblasts and thyroid antigen-specific L3T4⁺ T cell clones, but not with antithyroid antibodies. Okayasu, I., *Clin. Immunol. Immunopathol.* 36(1):101-109 (1985); Charreire, J. et al., *Eur. J. Immunol.* 12(5):421-425 (1982); Romball, C.G. et al., *J. Immunol.* 138(4):1092-1098 (1987); Maron, R. et al., *J. Immunol.* 131(5):2316-2322 (1983). In addition, thymectomy has been shown to prevent the development of the disease. Okayasu, I., *Clin. Immunol. Immunopathol.* 36(1):101-109 (1985). T cells from animals with lymphocytic thyroiditis have been shown to have cytotoxic activity for cultured thyrocytes *in vitro* and CD8⁺ cells have been demonstrated to proliferate in response to thyroglobulin. Creemers, P. et al., *J. Exp. Med.* 157(2):559-571 (1983); Canonica, G.W. et al., *Clin. Immunol. Immunopathol.* 36(1):40-48 (1985).

Based on the above discussion, by eliciting a cellular immune response to the thyroid which parallels Hashimoto's disease, cytolysis of thyroid cancer cells can be effected. Inducing a "Hashimoto-like" thyroiditis in thyroid cancer patients is desirable for several reasons. The inflammation would be thyrocyte-specific, and thus be unlikely to affect other organs. The immune response would be directed towards micrometastasis which is not detectable by any current assay procedure and would be missed during thyroidectomy. This would provide a means of clearing these cells potentially more effective than ¹³¹I and a greater likelihood of cure from thyroidectomy. This approach could also be effective against cancers that did not concentrate iodine, for which there is no present therapy. In addition, while normal thyroid cells would also be destroyed, the effects of hypothyroidism can be easily and completely resolved by treatment and are trivial compared to the effects of progressive thyroid cancer. In any case, all current therapies for thyroid cancer result in hypothyroidism, and immunotherapy offers fewer additional risks than radiation or

surgery. Thus, immunotherapy of thyroid cancer has several advantages when compared to conventional therapy for thyroid cancer.

Several lines of investigation support the efficacy of inducing thyroiditis-like cellular immunity to treat thyroid cancer. While thyroid cancer is reported to occur in patients with Hashimoto's thyroiditis, there are several reasons why augmented antithyroid immune responses would be effective in preventing the development of thyroid cancer. Several studies have reported that thyroid cancer is seen solely in patients with localized thyroiditis surrounding a solitary Intrathyroidal mass that was a focus of papillary cancer. Mauras, N. et al., *J. Pediatr.* 106(6):895-898 (1985); Maceri, D.R. et al., *Laryngoscope* 96(1):82-86 (1986). This subgroup of patients may not have had Hashimoto's disease, but in fact had tissue inflammation mimicking thyroiditis as a response to their malignancy. Mazzaferri, E.L., "Thyroid Cancer," Ch. 43:319-331 (Becker, K.L. ed.) *Principles and Practice of Endocrinology and Metabolism*, J.B. Lippencott (Philadelphia PA 1990); Cooper, D.S. et al., *Endocrinol. Metab. Clin. North Am.* 19(3):577-591 (1990). This mislabelling may have arisen from many investigators' identifying thyroid cancer patients with serum antithyroid antibodies as having thyroiditis, a problem with several studies on this subject. Mauras, N. et al., *J. Pediatr.* 106(6):895-898 (1985); Maceri, D.R. et al., *Laryngoscope* 96(1):82-86 (1986). When patients with diffuse goiter or hypothyroidism are considered separately, they have a much lower rate of malignancy than that found in normal patients on autopsy studies. Maceri, D.R. et al., *Laryngoscope* 96(1):82-86 (1986). The few cancers described in patients with generalized lymphocytic thyroiditis are localized and have no regional or distant metastasis. Mauras, N. et al., *J. Pediatr.* 106(6):895-898 (1985); Maceri, D.R. et al., *Laryngoscope* 96(1):82-86 (1986); Hoie, J. et al., *J. Surg. Oncol.* 37(3):147-151 (1988). Given the fact that chronic inflammation is often thought to predispose to the development of cancer, the finding that cancer is seen less often in patients with chronic, diffuse thyroiditis indicates that the specific antithyroid immune response could control neoplastic thyroid cells.

Two groups have previously tried to induce thyroiditis as a treatment for thyroid cancer with limited success. One group used a crude extract of homogenated autologous thyroid cancer to immunize three patients with widely-metastatic thyroid cancer. Amino, N. et al., *Cancer* 36(3):963-973 (1975). Two of the patients were anergic at the time of immunization, and showed no response to either the thyroid cancer or control antigens. The one patient who was not anergic did demonstrate a response to the vaccine and had a 33% decrease in tumor mass that persisted for

over a year. In contrast, more recent studies which used acid-modified thyroglobulin to immunize eight patients with either papillary or follicular cancer were able to induce antithyroglobulin antibodies in five of the patients. Gerfo, P.L. et al., *Surgery* 94(6):959-965 (1983). Two of the patients with thyroglobulin antibodies also developed thyroiditis, with one of the two having a 30% regression of tumor mass. Another patient without documented thyroiditis also had stabilization of the lung lesions (lung metastases were not biopsied) after immunization. Despite this success, antithyroglobulin antibody titers were not high in these patients, and it was difficult to evaluate the degree of immune response to immunization due to interference by circulating thyroglobulin. In addition, considering the present understanding of the pathogenesis of thyroiditis, thyroglobulin may not be the proper target antigen to induce thyroiditis. While neither of these studies demonstrated complete success, they indicate that thyroiditis can be induced in humans through immunization and suggest that the induction of thyroiditis may have an anti-tumor effect on thyroid cancer.

Evaluation of Antigens Potentially Useful In Induction of Thyroid-Specific Immunity in Thyroid Cancer Patients. Given that thyroid cancer regressions have been associated with induced immunity to thyroid cells, and that progressive thyroid cancer is associated with defects in cellular immunity, several methods of inducing and augmenting antithyroid cellular immunity are herein considered. While there are no documented thyroid cancer-specific antigens, it is fortunate that these cancers have been demonstrated to express thyroid-specific antigens. Because these thyroid antigens are human autoantigens, they are known to be immunogenic in man and are associated with human T cell cytotoxicity for thyrocytes. Thus, human thyroid autoantigens would present favorable targets of thyroid cancer-specific immunotherapy, particularly since the normal tissue is essentially expendable.

There are several identified thyroid autoantigens: thyroglobulin, thyroid peroxidase (TPO), the TSH receptor, and more recently, a 64 kDa antigen. Charreire, J., *Adv. Immunol.* 46:263-334 (1989); Weetman, A.P., *Clin. Exp. Immunol.* 80:1-3 (1990); Bech, K. et al., *Clin. Endocrinol. (Oxf.)* 11(1):47-58 (1979); Dong, Q. et al., *J. Clin. Endocrinol. Metab.* 72(6A):1375-1381 (1991). Each have unique features which may offer advantages if used to induce thyroid-specific immunity. The 64 kDa antigen was recently identified through screening of a thyroid cDNA library and has been shown to be recognized by half the patients with Graves' disease. Dong, Q. et al., *J. Clin. Endocrinol. Metab.* 72(6A):1375-1381 (1991). It may be a membrane antigen, however there is no evidence that it is associated with destructive immunity to thyroid

cells. In addition, its presence on thyroid cancer cells is unknown, but is reported to be present on other tissues, including muscle cells. Dong, Q. et al., *J. Clin. Endocrinol. Metab.* 72(6A):1375-1381 (1991). The 64 kDa antigen thus appears to be currently the least viable candidate antigen for immunotherapy.

- 5 The TSH receptor is also a membrane antigen specific to thyroid cells. It has recently been cloned and identified as an analogue of the rhodopsin receptor family. Parmentier, M. et al., *Science* 246(4937):1620-1622 (1989). It has a large extracellular N-terminal domain that has unique, potentially antigenic sequences. Wadsworth, H.L. et al., *Science* 249(4975):1423-1425 (1990). However, there may be several problems
- 10 in using this antigen for immunotherapy. The antigen is not commonly associated with immune responses that lead to destruction of thyroid cells (Burman, K.D. et al., *Endocrinol. Rev.* 6(2):183-232 (1985)) and no evidence of cytotoxic T cell responses is seen in Graves' disease. Antibodies against the TSH receptor may be helpful in that they could block the receptor and prevent stimulation of the cancer by TSH.
- 15 However, immunizing with this antigen may result in thyroid stimulating antibodies which could stimulate tumor growth. Bagnasco, M. et al., *J. Clin. Endocrinol. Metab.* 69(4):832-836 (1989). Thus, immunotherapy involving the induction of immunity to the TSH receptor above does not appear feasible.

- The two thyroid autoantigens with the greatest potential as immunogens for
- 20 thyroid cancer are thyroglobulin and thyroid peroxidase (TPO), both associated with destructive thyroiditis. Thyroglobulin was the first recognized thyroid autoantigen and the first to be purified. Weetman, A.P. et al., *Endocrinol. Rev.* 5(2):309-355 (1984). It has been closely associated with thyroiditis, and is the major antigen in some animal models of thyroiditis. Okayasu, I., *Clin. Immunol. Immunopathol.* 36(1):101-109 (1985);
- 25 Charreire, J. et al., *Eur. J. Immunol.* 12(5):421-425 (1982); Romball, C.G. et al., *J. Immunol.* 138(4):1092-1098 (1987); Maron, R. et al., *J. Immunol.* 131(5):2316-2322 (1983); Creemers, P. et al., *J. Exp. Med.* 157(2):559-571 (1983); Canonica, G.W. et al., *Clin. Immunol. Immunopathol.* 36(1):40-48 (1985). However, these animal models of thyroiditis may not closely mimic the disease in man.

- 30 The thyroiditis induced by immunization with thyroglobulin is almost uniformly self-limited and does not result in the total destruction of the thyroid gland. Wick, G. et al., *Adv. Immunol.* 47:433-500 (1989); Krco, C.J. et al., *J. Immunogenet.* 17(6):361-370 (1990). In addition, immunization with thyroglobulin does not induce the formation of anti-TPO antibodies, which are seen in both animals with spontaneous thyroiditis
- 35 and humans with Hashimoto's disease. Antithyroglobulin antibodies do correlate with

disease activity in Hashimoto's patients, but to a lesser extent than anti-microsomal antigen (TPO) antibodies. Weetman, A.P., *Clin. Exp. Immunol.* 80:1-3 (1990). The induction of thyroiditis in animals is also highly dependent on the method of immunization, and only particular strains of animals develop the disease on immunization. Wick, G. et al., *Adv. Immunol.* 47:433-500 (1989). The antigenicity of thyroglobulin is also variable, a phenomenon that in humans and experimental animals seems to be related to the iodine content of the thyroglobulin. This is supported by the observation that thyroiditis is more common in geographic areas where there is dietary replacement of iodine. Sundick, R.S., *Immunol. Ser.* 52:213-228 (1990).

Recent work in animals has shown that a T cell epitope in thyroglobulin requires an iodination site. MacKenzie, W.A. et al., *J. Clin. Endocrinol. Metab.* 64(4):818-824 (1987). It therefore may be very difficult to standardize the antigenicity of thyroglobulin. Importantly, thyroglobulin is not a membrane protein, and since it is released from the cells it may act as a blocking antigen that could blunt the induction of immunity or deflect the immune response away from thyroid cells. Thus, although thyroglobulin is associated with destructive thyroiditis in both man and animals, there are several drawbacks in employing this antigen to induce cellular immunity in patients with thyroid cancer.

There are several advantages to the use of TPO as an antigen. In contrast to animal models of thyroiditis induced by immunization with thyroglobulin, spontaneous thyroiditis in both humans and experimental animals is most closely associated with evidence of immunity to TPO. Weetman, A.P. et al., *Endocrinol. Rev.* 5(2):309-355 (1984); Wick, G. et al., *Adv. Immunol.* 47:433-500 (1989). This type of thyroiditis closely mimics the type of immune reaction required to destroy a thyroid cancer cell, since it results in thyrocyte cytolysis and the total destruction of the thyroid. Antibodies to TPO closely reflect the degree of inflammation in the thyroid gland in thyroiditis, and there is T cell sensitization to TPO in most patients. TPO is also a membrane antigen, and therefore presents a better target for immunotherapy than thyroglobulin.

The presence of TPO on most follicular cancers and about one half of papillary cancers has also been documented. Fragu, P. et al., *J. Clin. Endocrinol. Metab.* 45:1089-1096 (1977). It may in fact be present on a higher percentage of thyroid cancers, since many of the older studies measured TPO expression in thyroid cancer by examining tumors for functional peroxidase activity, while more recent immunohistologic studies have identified non-functional TPO in many cancers.

- 22 -

DeMicco, C. et al., *Cancer* 67:3036-3041 (1991). Although TPO resides primarily on the apical membrane and microvillar surfaces in normal thyroid follicular cells, it can be observed on the plasma membrane in inflamed thyrocytes and thyroid cancer cells. Christor, K. et al., *Acta. Histochem.* 58:275-289 (1977). Its expression appears to be induced by local inflammation serving to reinforce the autoimmune responses. Roman, S.H. et al., *Autoimmunity* 2(3):253-263 (1989). These findings indicate that TPO exhibits two important characteristics: it is an antigen associated with cytolytic immunity to thyroid cells and is a membrane antigen associated with a large proportion of thyroid tumors.

Patients with thyroid cancer often show evidence of sensitization to TPO, indicating at least a primary immune response to this antigen. Twenty-five to 50% of patients (depending on the technique) with papillary or follicular cancer have antibodies to TPO, and there have been scattered reports of the documentation of cellular immunity to "microsomal antigen". Pacini, F. et al., *Acta, Endocrinol.* (Copenh.) 119(3):373-380 (1988); Juhasz, F. et al., *Cancer* 63(7):1318-1326 (1989). Unfortunately, until recently many of the studies concerning the immune reactivity to TPO suffered because the identity of the microsomal antigen as TPO was not known, and as a result both the serologic and cellular immune assays were less sensitive than those for thyroglobulin. However, even the results of these older studies support the premise that TPO stimulation of anti-thyroid immunity in patients with thyroid cancer, is advantageous in inducing a secondary immune response rather than a primary one.

Despite the many advantages in using thyroid peroxidase, there are some potential disadvantages. Only one study has shown the effectiveness of affinity purified porcine TPO in the induction of thyroiditis. Kotani, T. et al., *Clin. Exp. Immunol.* 80(1):11-18 (1990). There is also extensive homology between TPO and myeloperoxidase (Kimura, S. et al., *Proteins: Structure, Function & Genetics* 3:113-120 (1988)), and immunization with the whole molecule might induce a cross-reacting immune response leading to the immune destruction of leukocytes, although this is not seen in patients with thyroiditis. Also, TPO may not be present on all thyroid cancers, which may somewhat limit its usefulness.

SPECIFIC EXAMPLE I - TPO EPITOPE IDENTIFICATION AND IMMUNOASSAY

Materials and Methods

Patients. Twenty-five patients with Hashimoto's disease were studied. They were diagnosed because of goiter or hypothyroidism and evidence of anti-microsomal antibodies in a titer greater than 1:1600 as detected with an agglutination assay (Ames

Diagnostics, Ames IA). Study serum was obtained from all patients at the time of their enrollment and was frozen at -70°C until use. Patients with non-autoimmune thyroid disease (multinodular goiters) who had no evidence of anti-microsomal antibodies by agglutination immunoassay were used as controls.

- 5 **TPO Complementary DNA (cDNA).** A Bluescript SK plasmid with the full length (3.1 kb) cDNA for human TPO inserted into the *NotI/XbaI* (5' - 3') restriction sites was a gift of Dr. Basil Rapoport, VA Medical Center, San Francisco CA. This plasmid contained the (longest) complete, full length coding sequence and therefore did not include the alternative splicing segments with the internal deletion that had
10 been previously reported in Kimura, S. et al., *PNAS (USA)* 84:5555-5559 (1987); Nagayama, Y. et al., *J. Clin. Endocrinol. Metab.* 71:384-390 (1990) and Zanelli, E. et al., *Biochem. Biophys. Res. Commun.* 170:735-741 (1990).

- Immunoprecipitations.** Immunoprecipitations of *in vitro* translated TPO were carried out as follows. The Bluescript plasmid containing the cDNA for human TPO
15 was digested separately with *XbaI*, *Clal*, *BamHI* and *BglII* to produce C-terminal truncations yielding translation products of 933 (full length), 631, 455 and 120 amino acids, respectively (designated TPO(1-933), TPO(1-631), TPO(1-455) and TPO(1-120)). The TPO plasmid was also digested with *Eco47 III* and *BamHI*. The ends of this linearized plasmid were then filled in with Klenow and the plasmid was subsequently
20 ligated to itself. This plasmid was then digested with *XbaI* to yield a translation product with an internal deletion from amino acids 4 to 455 (TPO(Δ 4-455)). After agarose gel electrophoresis confirmed digestion of the plasmids, these templates were incubated with T3 RNA polymerase and nucleotide triphosphates for 45 minutes at 37°C to produce sense RNA. Translation was then performed by incubating the RNA
25 with rabbit reticulocyte lysate (Promega, Madison WI) and ³⁵S-methionine according to the vendor's protocol. Translation products were analyzed by SDS-PAGE and autoradiography and were found to have the expected molecular weight before being used in the immunoprecipitations (data not shown). Immunoprecipitation was then performed by mixing 100 μ l of a 1:2 dilution of either Hashimoto's or normal sera, or
30 10 μ g of a monoclonal antibody to TPO, with 7500 CPM of *in vitro* translated product for one hour at 37°C. This was followed by the addition 50 μ l of Protein A agarose. The agarose was mixed thoroughly for approximately 1 hour at 37°C, and then allowed to settle from the mixture. The supernatant fluid was removed and the agarose was subsequently washed with PBS. The washed agarose was then treated

- 24 -

with sample buffer containing beta mercaptoethanol and SDS to solubilize the bound proteins for subsequent analysis by SDS-PAGE and autoradiography.

Production of Recombinant TPO. The full length coding sequence for TPO was inserted into the *NcoI* restriction site of the *E. coli* expression vector pET 3d using appropriate adapters. See Studier, F.W. et al., *Meth. Enzymol.* 185:60-89 (1990). This construct was grown in *E. coli* HMS174(DE3)pLysS to an OD_{600nm} of 0.4 - 0.5. A small sample was removed for later analysis and IPTG (isopropyl- β -D-thiogalactopyranoside) was added to the rest of the culture at a final concentration of 0.4 mM. This culture was grown for three hours at 37°C and the bacteria were harvested by centrifugation (4000 g for 20 minutes) and resuspended in 25 ml of lysis buffer (10 mM phosphate, 30 mM NaCl, 0.25% Tween, 10mM beta mercaptoethanol, 10 mM EDTA, 10 mM EGTA, containing 1 mM PMSF, 0.5 mg/ml leupeptin and 0.7 μ g/ml pepstatin A). The treated bacteria preparation was then incubated with 1 mg/ml lysozyme for 30 minutes in an ice bath and sonicated with four, 30 second pulses at the end of the incubation. NaCl was added to bring the salt concentration to 500 mM and the suspension was then spun at 10,000 g for 30 minutes. The supernatant (henceforth called lysate) was saved and brought to a final protein concentration of 2.5 mg/ml using column buffer (10 mM phosphate, 0.5 M NaCl, 1 mM azide, 10 mM beta mercaptoethanol and 1 mM EGTA with PMSF, leupeptin and pepstatin A).

Protein from the bacterial lysate was then analyzed by SDS-PAGE with Coomassie staining, or electro-transferred onto nitrocellulose paper. This transfer was then immunoblotted with the mouse monoclonal antibody against TPO (1 μ g/ml) and several high titer anti-TPO sera from Hashimoto's patients (1:100 dilution in phosphate buffered saline (PBS) with 1% BSA) at room temperature, with shaking, overnight. These strips were washed and then incubated with alkaline phosphatase labelled anti-human IgG or anti-mouse IgG, as appropriate for the primary antibody. After a final wash, the blots were developed using BCIP/NBT substrate solution.

A fragment of TPO cDNA was also placed into the *E. coli* expression vector pMalcRI (New England BioLabs, Beverly, MA) in the following manner. The TPO cDNA was digested with *Bam*HI and ligated to an adapter having an *Eco*RI 5' end. The ligation product was then digested with *Xba*I and ligated into pMalcRI that had been digested with *Eco*RI and *Xba*I (5' - 3'). This construct encoded a fusion protein in which the amino terminal portion is maltose binding protein (MBP) minus its leader sequence followed first by the sequence IEGRISEF (one letter amino acid code) and

- 25 -

then amino acids 456-933 of human TPO. This construct was transformed into *E. coli* XL-I and grown at 37°C with shaking until OD_{600nm} readings reached approximately 0.3. IPTG was added at a final concentration of 0.3 mM and the bacteria were cultured for two more hours. The cells were harvested by centrifugation and lysate
5 was produced as described above.

The lysate was run over an amylose affinity column to isolate the MBP fusion proteins according to the vendor's protocol (New England BioLabs), after which the column was washed with 10 volumes of column buffer with 0.05% Tween 20. The fusion protein was eluted using a column buffer containing 10 mM maltose. One ml
10 fractions were collected and assayed for protein by dye binding technique (BioRad, Richmond CA). Fractions containing protein were pooled and analyzed using SDS-PAGE. The proteins were then transferred to nitrocellulose membranes using standard techniques. Western blots of the electrophoresis were performed with 1:100 dilutions of normal sera, sera from TPO antibody positive Hashimoto's patients, and
15 a 1:10,000 dilution of a rabbit antisera to MBP. Binding inhibitions were performed by preincubating the sera with 50 µg of native human thyroid microsomal antigen (prepared as described in Portmann, L. et al., *J. Clin. Endocrinol. Metab.* 61:1001-1003 (1985)) for four hours at room temperature before incubation with the nitrocellulose strip.

20 **ELISA Studies.** Ninety-six well microtiter plates were coated with 1 µg/ml anti-TPO monoclonal antibody, 100 µl/well, in bicarbonate buffer, pH 9.6, overnight at 4°C. The plates were washed, and blocked with 200 µl of 1% BSA in PBS for at least two hours. The plates were again washed with PBS, 0.05% Tween 20 (PBST), and incubated with 6 µg/ml human thyroid microsomes (prepared as described in
25 Portmann, L. et al., *J. Clin. Endocrinol. Metab.* 61:1001-1003 (1985)) for two hours at room temperature. The plates were then washed and either used immediately or filled with blocking buffer and stored at 4°C.

Hashimoto's patient sera were diluted 1:500 in PBS with 1% BSA, then diluted 1:2 with either the MBP-TPO fusion protein or an equimolar amount of a control fusion
30 protein, maltose binding protein-LacZα. These dilutions were then incubated overnight at room temperature with gentle shaking, before being added to the microtiter plates. The sera were then incubated for four hours at room temperature, after which the plates were aspirated and washed. A 1:1000 dilution of alkaline phosphatase conjugated, anti-human IgG (Sigma, St. Louis MO) was then added and the plates
35 were incubated for two hours at room temperature. The plates were then washed, p-

- 26 -

nitrophenyl phosphate substrate was added and the $A_{405\text{nm}}$ was read after 45 minutes.

Results

Immunoprecipitation Studies. ^{35}S -labelled TPO fragments and the full length (933 amino acid) TPO protein were produced by *in vitro* translation and subjected to immunoprecipitation. As shown in Figure 1, six Hashimoto's patients' sera immunoprecipitated the full-length TPO produced from a cDNA linearized with *Xba*I (lanes labeled *Xba*I), but did not precipitate a fragment corresponding to the first 455 amino acids (labeled *Bam*HI for the enzyme used to cut the cDNA). A mouse monoclonal antibody against TPO amino acids 266 to 281 as discussed in Finke, R. et al., *J. Clin. Endocrinol. Metab.* 71:53-59 (1990), was used as a positive control and precipitated both the full-length protein TPO (1-933) and TPO (1-455), but not the smaller fragment TPO ((1-120), labeled *Bgl*II). This confirms that the TPO (1-455) fragment was present and could have been precipitated if the Hashimoto's patients' sera antibodies bound to it. This suggested the absence of local autoantibody binding epitopes in the first 455 amino acids of the translation product.

In order to confirm these studies and further localize putative autoantibody epitopes in the TPO molecule, two additional TPO fragments were produced by *in vitro* translation and immunoprecipitations were performed. Figure 2 summarizes the results from the monoclonal antibody binding to an epitope from amino acid 266 to 281 (presented in the left column) compared to those from Hashimoto's patients' sera (presented in the right column). The patient sera consistently bound only fragments containing the amino acid sequences after 455. All six Hashimoto's patients immunoprecipitated TPO (1-631) and TPO (Δ 4-455). As expected, the mouse monoclonal antibody precipitated TPO (1-631) but not TPO (Δ 4-455), the latter having an internal deletion which includes the monoclonal antibody binding site. Taken together, these results suggested the presence of autoantibody epitopes in the carboxyl-half of the TPO molecule, with at least one epitope localized between amino acids 456 and 631.

Studies Using Bacterial Expression Systems. In order to confirm the results of the immunoprecipitation studies using other techniques, *E. coli* were transformed with pET 3d vector expressing the full length cDNA for TPO. The transformed colonies were isolated and grown in culture to an OD of 0.6. The cultures were then split, with half the bacteria being exposed to IPTG. The bacteria were isolated and a crude lysate was produced and subjected to SDS-PAGE (100 μ g of protein lane). The gel

- 27 -

was then transferred to nitrocellulose paper, and the paper was immunoblotted with four sera from patients with Hashimoto's thyroiditis and high-titer anti-TPO antibodies (depicted as H1 through H4 in Figure 3) and a monoclonal antibody against TPO (depicted as M anti-TPO). Referring now to Figure 3, Western blots of lysate from pET 3d (TPO) transfected bacteria induced with IPTG (depicted as + lanes) revealed a product which was identified by the mouse monoclonal antibody (referenced with an arrow), but not by the Hashimoto's patient sera. Since the molecular weight of this material was uniformly less than 48 kDa (approximately half the expected molecular weight of TPO) and the mouse monoclonal antibody identified an epitope early in the coding sequence (from amino acids 266 to 281) in the TPO molecule, it appeared that either only the N terminal of the TPO molecule was being translated or that the molecule was being fully translated and the carboxyl half was undergoing proteolytic digestion. Transfection of this vector into protease-deficient bacteria (not shown) did not alter the type or quantity of TPO protein produced, thus suggesting that the short TPO product was due to translation termination rather than proteolytic digestion.

In an attempt to find a more efficient expression vector, pMalcRI (New England BioLabs, Boston MA) containing the coding sequence for MBP, a bacterial protein that binds and transports maltose, followed by the sequence of the insert cDNA nucleotides coding for TPO amino acids 456-933 was used. This construct has three advantages. The bacterial sequence appears to stabilize the subsequent translation of the eukaryotic RNA sequence. The resulting fusion protein can be affinity purified from whole bacterial lysate on an amylose column. In addition, a Factor X α cleavage site is inserted in the pMALcRI vector between the MBP coding region and the polylinker insertion site so that the fusion protein can be cleaved from MBP to release the protein of interest.

The resulting plasmid (denoted pMAL-TPO 456-933) was transformed into *E. coli* XL1, and the transfected colonies were isolated and grown to an OD of 0.6. The bacteria were induced with IPTG, and cultured for 90 minutes. The cells were then harvested and a crude lysate was produced. This lysate was run over the amylose affinity column. The column was washed and the bound proteins were specifically eluted with 10 mM maltose-containing buffer. These proteins were separated by SDS-PAGE, and transferred to nitrocellulose paper.

The fusion proteins were analyzed for reactivity with Hashimoto's sera using Western blots. Referring now to Figure 4, the lane marked α MBP was probed with a rabbit antisera to MBP. This lane shows all the electrophoresed proteins that were

- 28 -

isolated from the amylose affinity column. The Hashimoto's patient sera react with multiple molecular weight fusion proteins in three general patterns of reactivity (A, B and C). A range of fusion products was revealed from 85 kDa (full-length MBP fused with amino acids 456 to 933 of TPO) to approximately a 42 kDa band (the molecular weight of the MBP without a translated fusion product). See Figure 5. Reactivity with many of the bands above approximately 48 kDa was shown in the Hashimoto's sera, and none of the normal sera showed reactivity. The Hashimoto's patients showed several different patterns of reactivity with the smaller fusion proteins (depicted as dotted and clear arrows in Figure 4), suggesting the presence of unique epitopes in the smaller transcripts that are recognized by sera from different subgroups of these patients. Overall, 24 of 25 Hashimoto's patients with anti-microsomal (agglutination) titers of greater than 1:1600 had positive reactivity to this fusion protein on the immunoblots, but there was no relationship between anti-microsomal antibody titer and immunoblot intensity (data not shown).

The fragments smaller than 85 kDa most likely represent C-terminal TPO truncations rather than N-terminal MBP truncations for two reasons. First, N-terminal truncations of even 10-20 amino acids would not bind to the amylose affinity matrix and would therefore not be isolated in the fractions analyzed by SDS-PAGE (Personal communication, Paul Riggs, New England Biolabs). Second, if there were N-truncations of the fusion protein, the most likely cause would be proteolysis. This latter possibility was addressed by the use of several protease inhibitors (PMSF, leupeptin, pepstatin A and EDTA) and by expressing the fusion protein in the protease-deficient *E. coli* strain SW6AA2 (*lon*, *rpoH* am165). However, neither of these manipulations significantly decreased the quantity of smaller fusion peptides, suggesting they were not proteolytic fragments.

Five of the Hashimoto's patients demonstrating the most intense reactivity with the fusion protein on Western blot were analyzed for cross-reactivity between native TPO and the recombinant MBP-TPO fusion protein. Referring now to Figure 6, plus (+) lanes are blots probed with Hashimoto's sera preincubated with native thyroid microsomes, while minus (-) lanes are the same sera preincubated with a control protein (BSA). In all five sera the antibody binding to the recombinant TPO fusion protein was completely inhibited by preincubation with a ten-fold molar excess of native TPO. This indicated that the epitopes recognized by the patients' sera in the recombinant fusion proteins were present in native TPO.

- 29 -

Because of the possibility that multiple antigenic sites might exist in TPO between amino acids 456 and 933, new pMALcRI constructs were made that expressed smaller portions of the TPO molecule. Specifically, pMALcRI-TPO 456-631 was created, which produced a MBP fusion protein containing TPO amino acids 456-631, and pMAL TPO 632-933 which produces a MBP fusion protein containing TPO amino acids 632-933. The fusion proteins produced by these plasmids were independently recognized by autoantibodies from patients with Hashimoto's disease verifying the presence of multiple autoantibody binding sites in the TPO sequence from AA 456-933. Referring now to Figure 7, Patient 2 not only reacted with the AA 632-933 fragment, but reacted with a wide variety of bands produced from this fragment. Neither patients' binding was inhibited by MBP, confirming the specificity of the antibodies for the TPO sequences. In total contrast, no autoantibody binding could be identified in the N-terminal half (AA 1-455) of the TPO molecule. Maastricht, J. et al., *J. Clin. Endocrinol. Metab.* (accepted for publication 1992). This may be explained by the fact that the N-terminal half of the TPO molecule demonstrates greater homology with other peroxidase enzymes, such as myeloperoxidase, than does the amino acid sequence beyond amino acid 455. See Kimura, S. et al., *Proteins: Structure, Function, and Genetics* 3:113-120 (1988). This suggests that the specificity of the human immune response for TPO autoimmune thyroiditis relates to recognition of sites not shared with myeloperoxidase.

When screening large numbers of patients for reactivity to recombinant peptides corresponding to TPO amino acid sequences 517-630 and 631-933 (see Figures 9A and B), vastly different reactivity is seen. While >80% of patients react to AA 631-933, only 20% of patients react to epitopes located between AA 517-630. However, in these latter patients there is marked reactivity to this region. This suggests unique reactivity in patients with thyroiditis, and potential differences in reactivity which may relate to disease pathogenesis.

It also appears that the region between amino acids 633 and 933 contains more than one antibody binding site. This is supported by data indicating that only half of the patients who bind to the amino acid 633 to amino acid 933 fragment also bind to a peptide fragment corresponding to amino acids 633 to 768. This indicates that the patients who do not bind to the 633 to 768 fragment bind to a region involving amino acids 768 to 933.

ELISA Inhibition Assays. Figure 19 shows a graphical representation of an ELISA for detection of human antibodies against TPO epitopes. Plates are coated

- 30 -

with monoclonal antibodies directed against MBP and partially purified MBP-TPO fusion protein is incubated, and bound by the monoclonal antibody. After washing, human sera diluted 1:400 is added to the well and binds to the TPO epitope (to prevent sera binding to bound MBP, the sera is preincubated with soluble MBP). The bound human antibody is then detected with anti-human IgG preabsorbed against mouse IgG. An enzyme substrate is then added to quantitate bound enzyme, which is proportional to the amount of bound human IgG. The assay can be adapted to measure antibody to any TPO epitope (or any other autoantigen) by substituting a different MBP-containing fusion protein).

ELISA inhibitions were carried out with seven patients having anti-TPO activity. The solid phase antigen used in the assay, of which the results are set forth in Figure 8, is native human TPO bound to the ELISA plate wells using the mouse monoclonal anti-TPO antibody. As shown in Figure 8, preincubation with the MBP-TPO (AA 456-933) fusion protein (depicted as striped bars) was compared to inhibitory binding to native TPO as compared with preincubation with a control fusion protein (MBP-LacZ α , depicted as solid bars). Preincubation with the MBP-TPO fusion protein inhibited binding to the native TPO 70-100% as compared to the control fusion protein which caused only 10-15% inhibition. In four of the eight patients, the inhibition with MBP-TPO was to the background levels of the assay. These results suggest that the majority of the autoantigen epitopes in native TPO are located in the area of the region of the molecule distal to amino acid 455.

SPECIFIC EXAMPLE II - IMMUNOTHERAPY

It is important to evaluate autoantibody reactivity to the newly identified localized epitopes of TPO because of the prevalence of antibodies to the thyroid microsomal antigen in several diverse patient populations. Elderly patients without evidence of overt thyroid disease, where up to 20% of individuals (primarily females) demonstrate autoantibodies as described in Spaulding, S.W., *Endocrinol. Metab. Clin. North Am.* 16(4):1013-1025 (1987), were the first individuals evaluated to determine if some of these patients had antibodies against the localized TPO determinants as a marker of true autoimmune disease. During the course of these studies sera from three patients with thyroid cancer were evaluated. The Western blots of Figure 10 depict studies of a patient with papillary thyroid cancer (Patient A), follicular thyroid cancer (Patient B) and Hashimoto's thyroiditis (Patient C). Reactivity with both types of fusion proteins and human TPO (lanes A, B, and C), as well as the lack of reactivity with MBP (lane D), is shown. While these patients were not actually "normal" elderly

- 31 -

individuals, all three demonstrated autoantibodies to the recombinant TPO epitopes. It appeared that these patients' antibodies were in lower titer than those found in most Hashimoto's patients. However their reactivity to the localized TPO epitopes was as great or greater than that seen to the whole, native TPO molecule. The fact that cancer patients would have antibodies to TPO despite clinically significant and locally progressive thyroid cancer appears paradoxical. However, none of these three patients, one with follicular cancer and two with papillary carcinoma, exhibited distant metastasis. Both of the patients with papillary cancer had a mononuclear cell infiltrate surrounding their cancers but still had evidence of local progression. Thus, there was no clear relationship between the presence of anti-TPO antibody and either the type of thyroid cancer or evidence of a local immune reaction. This suggested that patients with thyroid cancer had pre-existing immune responses to TPO and that antibody to TPO alone might not be sufficient to control thyroid cancer.

Purification of MBP-TPO Fusion Proteins. Because of the evidence of serologic responses to TPO in thyroid cancer patients, an evaluation of cellular immune responses to TPO in these patients was performed. It was postulated that some form of cellular immune response was necessary to generate the anti-TPO antibodies, and in autoimmune thyroiditis immune reactivity to TPO is associated with cellular cytotoxic responses to thyroid cells. Since cellular immunity to thyroid cells was likely to be a crucial factor in the immune response to cancer, it seemed an important factor to evaluate in cancer patients. Unfortunately, the immunoreactive TPO fusion proteins isolated from the amylose affinity column demonstrated a broad range of molecular weight fusion proteins, as shown in Figure 10, and were not of a purity suitable for use in cellular studies. This made defining the precise location of T cell epitopes difficult, and the problem was further compounded because the material appeared to contain a predominance of maltose binding protein sequence. In an attempt to resolve this problem, the pMALcRI plasmid was transfected into an *lon* and *rpoH* am165 deficient *E. coli* strain (data not shown) and fusion proteins were produced in these bacteria. This procedure still yielded fusion proteins with molecular weights below the expected size for the full-length fusion translation product. This again suggested that these smaller products were not the result of protease digestion. It appeared that since the shorter-length translation fragments bound and were affinity purified on the amylose column, these smaller fusion proteins must be C-terminal truncations since all but 10 amino acids of the N-terminal of MBP are necessary for binding to maltose (Personal communication, New England Biolabs). Thus, the largest

- 32 -

fusion proteins having a molecular weight equal to the combination of the full TPO sequence and MBP should contain the whole TPO sequence.

An attempt was made to isolate the full-length translation products by molecular weight separation. A number of techniques were evaluated for this, with HPLC proving to be the only technique that provided adequate separation of the different molecular weight MBP-TPO fragments. Unfortunately, the amount of material isolated by this method was minimal and insufficient for immunologic studies. A technique that employs preparative SDS-PAGE (Prep Cell, BioRad, Richmond CA) to isolate the different molecular weight MBP-TPO (AA 633-933) fusion proteins within \pm 2% of molecular weight was employed. As shown in Figure 11, the large number of different molecular weight fusion proteins isolated using amylose affinity columns (MAC-labelled lane) were subsequently separated by molecular weight using preparative SDS-PAGE. The full length translation product (FLP labelled lane) was isolated using this technique and is shown next to a number of other fractions isolated from the mixture (lanes A-L). This technique proved highly effective, yielding hundreds of micrograms of purified material that was strongly recognized by sera from patients with Hashimoto's disease, and it allowed the purification of a full-length fusion protein from whole bacterial lysate in twosteps. The final material was found to be free of other proteins and was also negative for endotoxin on limulus assay. This purified material was appropriate for use in T cell studies.

Cellular Immunity to MBP-TPO Fusion Proteins. The response of peripheral blood mononuclear cells to stimulation with TPO fusion protein (MBP-TPO AA 456-933), control fusion protein (MBP-LacZ α), media and PHA controls is shown in Figure 12. Cells were incubated with the antigens for 96 hours, then pulsed with tritiated thymidine and harvested 24 hours later. Specific proliferation was observed only to the 10 μ g/ml concentration of the MBP-TPO fusion. Lower concentrations of antigen showed no effect. MBP-TPO (AA 456-933) fusion proteins isolate from the Prep Cell were specifically recognized by peripheral blood mononuclear cells from patients with Hashimoto's thyroiditis, suggesting the presence of epitopes recognized by human T cells in the TPO sequence. The demonstration of this reactivity in thyroiditis patients prompted further examination of cellular responses in thyroid cancer patients.

In an attempt to evaluate cellular reactivity to the TPO fusion proteins, Prep Cell purified MBP fusion proteins representing the TPO fragments AA 456-633 and AA 633-933 were used to stimulate peripheral blood mononuclear cells from cancer patients. Prep Cell purified maltose binding protein-LacZ α fusion proteins and native

- 33 -

human TPO (isolated from thyroid microsomes using the Prep Cell) were used as controls. The cells were incubated for 96 hours with different concentrations of purified thyroid antigens, and were then pulsed with thymidine and harvested 24 hours later. As shown in Figures 13A and 13B, specific proliferation was seen in response to one of the TPO fragments (AA 456-633), but not to the other fragment (AA 633-933), control MBP fusion proteins (LacZ α) or native TPO. A third patient with follicular thyroid cancer was also evaluated, and showed a similar pattern although the total counts ranged from 200-600 total CPM. In two of the patients evaluated, specific proliferation in response to the AA 456-633 fragment was clearly demonstrated. This proliferation was not only greater than the MBP control, but also greater than that seen to native TPO. The reason for this is not clear, as the gravimetric concentrations of the proteins were equivalent and the molar concentrations of the different proteins were only 1.5 fold different. It is possible that the native TPO, which is heavily glycosylated, requires more processing by antigen-presenting cells, thus making it less effective than the recombinant protein in stimulating antigen-specific T cell proliferation. However, the stimulation seen with the TPO fusion protein was greater than that observed with the MBP-LacZ α fusion protein, indicating that the stimulation was not due to MBP amino acid sequences. These results indicated that there was pre-existing cellular immunity to TPO in the cancer patients and this immunity could be stimulated by recombinant protein fragments of TPO.

With the lymphocyte proliferation studies providing evidence of cellular immunity to the TPO proteins in cancer patients, studies were performed to determine if there was also evidence of cytotoxic activity related to this cellular immunity against TPO. The most likely source of T cells with this activity would be the lymphocytes infiltrating the thyroid cancer. The thyroidectomy specimen from one of the patients demonstrating proliferative activity to the synthetic TPO fragment in his peripheral blood lymphocytes was obtained. The patient underwent a thyroidectomy and was found to have papillary cancer with a localized mononuclear cell infiltrate surrounding his cancer. The lymphocytes from this thyroid gland were isolated, and the T cells were expanded by two different techniques: culture of the cells for two weeks with either supernatant fluid of lymphokine activated killer (LAK) cells or with IL2 alone. These expanded lymphocytes were then incubated with antigen alone or in combination with irradiated syngeneic antigen presenting cells (feeder cells) for 12 hours, and TNF production was measured 18 hours after the addition of antigen using a bioassay described in Flick, D.A. et al., *J. Immunol. Meth.* 68:167-175 (1984). As the

- 34 -

LAK supernatant expanded, T cells produced TNF in a non-specific manner, primarily in response to the syngeneic antigen presenting cells. In contrast, the IL2 stimulated cells showed TNF production only in response to the TPO fragments in the presence of antigen presenting cells and were not reactive with autologous mononuclear cells or other non-TPO fusion proteins as shown in Figure 14. This result indicated that there were lymphocytes infiltrating the thyroid that could specifically recognize TPO fragments in the presence of antigen presenting cells and respond by secreting TNF. In addition, the specificity of this response could be maintained while expanding the cells under appropriate culture conditions.

10 ***Induction of de novo Immune Response to Native TPO by TPO Fusion Proteins.*** With the finding that the fusion protein TPO fragments were immunologically recognized by the thyroid cancer patients, the characterization of the antigenicity of these constructs was expanded to determine whether the recombinant TPO fusion proteins could elicit an immunologic response to the native TPO molecule. This attribute would be essential if these constructs were to be used as immunizing agents in cancer immunotherapy. To examine the immunogenicity of the TPO constructs in animal models, three Balb-C mice received intraperitoneal immunizations with 2 mg/ml of Prep Cell purified MBP-TPO (AA 633-933) in Freund's adjuvant in an effort to produce antibodies against TPO. Serologic immune responses to the fusion protein and native TPO were evaluated in these animals. In the Western blots of Figure 15, specific reactivity with all of the fusion proteins (lanes A and B), as well as the MBP (lane D) was shown. Most importantly, specific reactivity with TPO (lane C, 100-105 kDa band) was seen. The protein stain of the gel is shown at the right of the blot for comparison. As shown in Figure 15, all three mice developed high titer, specific antibody to native TPO, clearly indicating the development of a serologic immune response to the fusion protein that cross-reacted with native TPO. This indicated that the TPO sequences in the fusion proteins induce antibodies reactive with the native TPO.

 The finding that these mice developed strong serologic reactivity to native TPO led to evaluation of potential cellular responses to TPO in these animals. The spleen of one of the immunized mice was harvested for a hybridoma fusion and a portion of the spleen preparation was used for cellular studies. The mouse splenocytes were immunized with Prep Cell purified MBP-TPO (AA 633-933) in complete Freund's adjuvant. This animal was documented to have developed specific antibody to native TPO through this immunization. See Figure 15, Mouse 2. Proliferation assays were

- 35 -

conducted using the purified fusion proteins, MBP and native TPO, as shown in Figure 16. As might be expected in an animal recently immunized with Freund's adjuvant, there was high background (spontaneous) proliferation of the cells. This made appraisal of the proliferation to the antigens difficult. However, the results suggest that the mouse lymphocytes proliferated in response to native TPO, although not significantly when compared to background. Further studies are currently being performed with several technical modifications: the animals are immunized with the fusion proteins in the absence of Freund's adjuvant and the assays are being performed in serum free media. The cellular immune response to native TPO is then measured.

SPECIFIC EXAMPLE III - IMMUNE RESPONSE TO TPO

Further evaluation of anti-TPO responses in cancer patients provides a more definitive understanding of which immune characteristics determine the extent of a patient's response to immune stimulation with TPO and assists in screening potential recipients for TPO-based cancer vaccine.

Immunoassay Techniques for the Determination of Antibody Responses to TPO in Cancer Patients. Serologic immunity to TPO is quantified by a number of different antibody assays in order to obtain a clear understanding of degree and specificity of this response. Traditional anti-microsomal antibodies are determined by commercial agglutination assay (Ames Diagnostics). Antibodies to human TPO are determined by ELISA using Prep-Cell-purified antigen with techniques described in Weetman, A.P. et al., *Clin. Chim. Acta.* 138(3):237-244 (1984). Antibody to the localized epitopes described in Specific Example I is assayed through Western blots of MBP fusion proteins containing specific TPO amino acid sequences (see Maastricht, J. et al., *J. Clin. Endocrinol. Metab.*, accepted for publication 1992) or through ELISA using Prep Cell-purified MBP-TPO fusion proteins. The latter assay involves coating 96-well plates with 1 µg/ml of fusion protein, then blocking the plates with BSA. The patient sera is run in quadruplicate, 1:2 serial dilutions (from 1:20) in phosphate buffered saline containing an excess of purified MBP, and the end-point titer determined. A control positive and negative sera is run on each plate to standardize the inter-plate variability. Antibodies to thyroglobulin are determined using a commercial agglutination assay (Ames Diagnostics) as a measure of overall serologic immune activity to thyroid antigens.

Examination of Cellular Immune Responses to TPO in Thyroid Cancer Patients. In order to determine if cellular immune responses to TPO are present in

- 36 -

the cancer patients being evaluated, several techniques are utilized. Proliferation in response to specific antigen is performed as previously described in Fisfalen, M.E. et al., *J. Clin. Endocrinol. Metab.* 66(4):776-784 (1988) using Prep Cell-purified native TPO isolated from thyroid microsomal fractions. See Yokoyama, N. et al., *J. Clin. Endocrinol. Metab.* 70:758-765 (1990). In addition, because of the divergent results between native and recombinant TPO in preliminary studies, at least three different MBP-TPO fusion proteins, MBP-TPO (AA 1-400), MBP-TPO (AA 376-631) and MBP-TPO (AA 456-933) are produced that will cover the entire amino acid sequence of TPO (with amino acid overlap to ensure all potential epitopes are identified). These fusion proteins are purified using the prep cell and used to stimulate peripheral blood mononuclear cells (PBMC) from the patients in a manner identical to the native TPO. Control stimulations are performed with MBP-LacZ α fusion proteins. If proliferation with MBP is identified, the patients are assayed using recombinant TPO fragments separated from MBP after cleavage with Factor X α .

Cytotoxic immunity for thyroid cells is measured with a chromium release assay using autologous thyroid cells as targets. These normal cells are isolated from normal, peri-tumor tissue in thyroidectomy specimens and grown in primary culture before labelling as described in Sack, J. et al., *Cancer* 59(11):1914-1917 (1987). TPO-specific cytotoxicity is determined using several assays. Specific production of TNF in response to antigen is performed as outlined in Flick, D.A. et al., *J. Immunol. Meth.* 68:167-175 (1984), with TNF production measured at several time points after the addition of antigen. Specific cytotoxicity for TPO-targets cannot be measured using thyroid cells because of the presence of other thyroid antigens. An alternate method uses autologous EB-lymphoblastoid cells transfected with the TPO gene and selected for TPO expression. The production of these targets and the cytotoxicity assay is described under the section of this Specific Example entitled *Induction and Characterization of CD8⁺T Cells Specific for TPO*.

Determination of TPO Expression on Thyroid Cancer. TPO expression is evaluated using immunohistochemical staining techniques discussed in DeMicco, C. et al., *Cancer* 67:3036-3041 (1991). Antibodies used for this detection involve monoclonal antibodies against several portions of the TPO molecule (see DeMicco, C. et al., *Cancer* 67:3036-3041 (1991); Finke, R. et al., *J. Clin. Endocrinol. Metab.* 71:53-59 (1990); and Hamada, N. et al., *J. Clin. Endocrinol. Metab.* 61(1):120-238 (1985)) as well as hetero-antisera raised against recombinant portions of the TPO molecule (see Figure 15). The tumor is also cultured, the cells harvested and whole

cell lysate prepared and subjected to SDS-PAGE, when possible. See Baker, J.R. Jr. et al., *J. Immunol.* 140(8):2593-2599 (1988). Western blots of these lysates are performed to determine if protein is produced *in vitro* by these cells. If immunoreactive TPO is not detected in the tumor, the thyroid cancer cells are cultured
5 and harvested as described in Rapoport, B. et al., *J. Clin. Endocrinol. Metab.* 58(2):332-338(1984), and RNA is isolated as described in Ledent, C. et al., *Endocrinol.* 129(3):1391-13401(1991). Northern blots of this RNA probed with labelled TPO cDNA (see Ozaki, S. et al., *Cell Immunol.* 185:301-316 (1987)) are used to detect evidence of transcription of the TPO gene, and to determine if the lack of expression is due to
10 a defect in transcription or translation. This may indicate why the tumors have recently lost the capability to produce TPO or if tumors may be producing minimal amounts of TPO protein or protein fragments not detected through the immunohistochemical staining techniques employed.

Induction of CD4/Helper Type Cellular Immunity to TPO. Techniques to
15 induce and amplify cellular immunity to TPO in patients with thyroid cancer should emphasize the induction of TPO-specific immunity in both CD4 and CD8 cellular subsets, as several animal tumor models have shown that the combined activity of both types of immune cells is most effective in mediating regression of established tumors. However, the methods of generating and characterizing TPO-specific
20 immunity in CD4 and CD8 cells is markedly different, as is the interaction of each subset with antigen. Therefore, the two T cell subsets are examined separately.

CD4⁺ T cells are thought to function by T cell antigen receptor (TCR) recognition of antigenic peptides presented in conjunction with Class II HLA molecules. This triggers the cells to produce lymphokines, such as IL2, IL4, TNF, INF γ
25 and GM-CSF, which stimulate a number of immune functions. These lymphokines normally have minimal inherent cytotoxicity, however they induce and activate direct cytotoxicity by CD8⁺ T cells, LAK cells and macrophages. In addition, it is possible that released lymphokines may cause autologous stimulation that results in CD4⁺ T cells evolving into active CD8⁺ cytotoxic T lymphocytes (CTL). Thus, CD4⁺ cell
30 cytotoxicity may occur through both direct and indirect means.

Induction and Expansion of TPO-specific CD4⁺ T Cells. The induction of CD4⁺ T cells specific for TPO is conducted on PBMC from patients with thyroid cancer. One of the advantages of studies involving CD4⁺ T cells is the relative ease (compared to CD8⁺ T cells) that these cells can be grown in culture. Because
35 antigen-presenting cells will take up exogenous antigen, process and present it in

- 38 -

conjunction with Class I MHC, soluble antigen and peripheral blood mononuclear cells are essentially the only requirements to induce growth and stimulation of CD4⁺ T cells. However, there are many variations in this process, especially in the composition of the antigen and the type of antigen-presenting cell, that can markedly influence not only the state of activation but the type of lymphokine produced. These variables are fully evaluated in the following studies.

TPO-specific CD4⁺ T cells are developed from PBMC which are purified from the peripheral blood of patients using Ficoll-Hypaque gradients. To produce the antigen-specific cells, approximately 1×10^6 cells/ml are incubated with purified forms of TPO antigen. These antigens include purified human TPO isolated from thyroid microsomes by the Prep Cell and recombinant TPO fragments coupled to MBP. It has previously been determined with cloning studies in autoimmune thyroiditis, that between 0.1 to 100 ng/ml of antigen should be incubated with the mononuclear cells as an optimal concentration for stimulation. See MacKenzie, W.A. et al., *J. Clin. Endocrinol. Metab.* 64(4):818-824 (1987). Antigen stimulation is done for five days in RPMI media supplemented with 10% pooled normal human serum, or in serum-free media (ABC media, Pan Data Systems, Gaithersburg MD). After the five days of stimulation, the reactive lymphoblasts are cultured for an additional seven days in media containing ten units/ml of recombinant IL2 (Genzyme, Boston MA) or 10% PHA supernatant of peripheral blood cells prepared as described in Higgs, J.B. et. al., *J. Immunol.* 140(11):3758-3765 (1988). After approximately seven days in IL2, the lymphoblasts are collected, washed and again stimulated with antigen for three days in the presence of irradiated, autologous peripheral blood mononuclear cells in IL2 free media. These alternating antigen/IL2 cycles are repeated approximately four to six times, with antigen stimulation always followed by IL2 stimulation.

Proliferative Response of TPO-specific T Cells. After these cycles, the cells are evaluated for antigen specificity through proliferation assays using purified antigen and irradiated antigen-presenting cells. Proliferative responses are determined using thymidine incorporation as described previously in Holoshitz, J. et al., *J. Clin. Invest.* 73(1):211-215 (1984). Approximately 15×10^4 cultured T cells and approximately 7.5×10^4 irradiated autologous PBMC are incubated together per well, with or without the antigen for approximately 72 hours. Cultures are then pulsed with ³(H) thymidine and harvested as described in Holoshitz, *supra*. Proliferated responses are assessed by comparing CPM obtained with the antigen to CPM obtained without the antigen, and with PHA-stimulated cells serving as a positive control. A stimulation index of

approximately three times background is usually considered positive. Stimulation indices of TPO antigen versus control antigen (such as tetanus toxoid) is compared to determine the enhancement of specific TPO responses achieved through the sequential stimulation cycles.

5 **Production of TPO-specific CD4⁺ T Cell Clones.** TPO responsive cells are also cloned using previously described limiting dilution techniques. See MacKenzie, W.A. et al., *J. Clin. Endocrinol. Metab.* 64(4):818-824 (1987) and Goronzy, J. et al., *Meth. Enzymol.* 150:333-341 (1987). This technique involves Percoll density gradient
10 purification of the viable lymphoblasts which are then re-suspended to a concentration of approximately 5 cells per 100/ml. These cells are then plated onto flat bottom 96-well microtiter plates (Costar) at approximately 100 μ l per well, over feeder cells consisting of autologous, irradiated EB transformed B cells or PBMC. The autoantigen are reintroduced at a concentration ranging from approximately 1 ng/ml to 1 μ g/ml. The cloned cells are then examined for proliferating cells under phase-contrast
15 microscopy. Those cells which appear to be responding are expanded through weekly repeated stimulations with feeder cells and antigen, and are then expanded to large populations with IL2.

Phenotyping of T Cells and T Cell Clones. The surface phenotype of the successfully propagated, TPO-specific cells and clones is determined using
20 cytofluorographic analysis as described in Lanier, L.L. et al., *Nature* 324(6094):268-270 (1986). Antibodies include: anti-CD5 (Becton-Dickinson), OKT11 (anti-CD2, Ortho-Diagnostics), anti-leu4 (anti-CD3, Becton-Dickinson), anti-leu3 α (anti-CD4, Becton-Dickinson), anti-leu2 α (anti-CD8, Becton-Dickinson), WT31 (anti- α β T cell receptor, Becton-Dickinson) anti-DR (Becton-Dickinson), anti-IL2 receptor
25 (Becton-Dickinson), TCR δ 1 (anti-TCR δ chain, T Cell Sciences) and W6-32 (anti-HLA A, B & C, Accurate Scientific). Two color staining is performed and the clones are judged positive only if greater than 90% of the cells express an antigen as compared to isotope control monoclonal antibodies labeled with the same fluorescent dye.

Localizing CD4⁺ T Cell Epitopes in TPO. It may be important to identify the
30 precise epitopes involved in the induction of CD4⁺ T cell immunity to TPO. These small peptide fragments are then coupled to a number of adjuvants in order to increase their immunogenicity and augment the immune response to native TPO. The localization of these epitopes involves the production of recombinant TPO fragments. This work is conducted in a manner similar to that described in Specific Example I and
35 Maastricht, J. et al., *J. Clin. Endocrinol. Metab.* 75:121-126 (1992). Essentially,

- 40 -

fragments of the cDNA for TPO are produced through digestion with specific endonucleases and Polymerase Chain Reaction (PCR). These fragments are ligated, in correct frame for translation, into pMALcRI. The plasmids created are used to transform XL-1 *E. coli*, and lysates of these cells are prepared. The MBP-TPO fusion proteins are isolated from lysate by amylose affinity chromatography and preparative SDS-PAGE. These fragments are used in proliferation assays to identify which TPO fragments contain the amino acid sequences recognized by the CD4⁺ T cells.

Once the epitope has been localized to approximately 20 amino acids using the TPO fragment fusion proteins, synthetic peptides are used to map the exact T cell recognition sequence. Because T cells normally recognize peptides of 6-12 amino acids in length, 12 amino acid peptides which overlap by 6 amino acids are constructed which correspond to suspected epitopes. The synthetic peptides are tested to determine if they induce proliferation in the TPO-specific T cell and clones. Those peptides with activity are subdivided into smaller peptides, each containing a fraction of the 12 amino acid sequence, to indicate the exact recognition site.

Alternative Studies. It is possible that despite favorable preliminary data, the recombinant proteins may not be entirely effective in inducing a TPO-specific CD4 immune response, or may only produce a response in a minority of patients. Several techniques are utilized to overcome this problem. The synthetic TPO fragments are cleaved from MBP and coupled to more potent adjuvants, such as KLH. See Bruderer, U. et al., *Immunol.* 64(3):385-390 (1988). The concentrations of these fragments may need to be varied, or several different fragments of the TPO molecule may need to be mixed together to provide adequate stimulation of many different anti-TPO T cell clones all recognizing different epitopes. Different types of antigen presenting cells may also be important in the induction of CD4 responses. Dendritic cells are more effective in presenting antigen than normal macrophages and are isolated from peripheral blood using monoclonal antibodies and flow cytometry, or preferably with monoclonal antibody-coated magnetic beads (Dynal). Normal, autologous thyroid cells may be useful in this context, especially if Class II antigens are induced with γ -interferon. In addition, it is possible that EB-transformed lymphoblastoid cells are a superior method for stimulating CD4 cells. These options are exercised if initial attempts to induce TPO-specific CD4 cells are not successful.

A major factor guiding the *in vitro* production of CD4 immunity may be the natural development of anti-TPO immunity in cancer patients *in vivo*. In this regard, studies previously discussed in this Specific Example, should serve as an indication

of the degree of CD4⁺ T cell sensitization and its relation to tumor TPO expression. Once the prevalence of this immunity is established, through the evaluation of large numbers of patients, subsequent studies focus on the specific conditions which affect the development of TPO-specific CD4⁺ T cell responses *in vivo*. In relation to this, several clinical factors are closely examined: tumor histology, stage, evidence of metastasis, nutritional status and prior treatments. It is possible that the anti-TPO response is maximal early in the course of the disease, and becomes attenuated by the presence of increased tumor burden, metastasis and chemotherapy. To maximize the yield of TPO-specific precursor CD4⁺ T cells for *in vitro* manipulation or expansion, it is important to understand the relationship between the tumor and anti-TPO responses and address whether endogenous TPO-specific CD4⁺ T cells immune responses modulate the biology of autologous tumors *in vivo*.

Induction and Characterization of CD8⁺ T Cells Specific for TPO.

Cytotoxicity of tumor cells by Class I MHC-restricted CD8⁺ cells has been demonstrated in a number of tumor models. See Mitsuya, H. et al., *J. Exp. Med.* 158:(3):994-999 (1983) and Anichini, A. et al., *J. Immunol.* 142(10):3692-3701 (1989). While technical problems are encountered in generating these cells, they offer the possibility of direct tumor lysis using restriction elements (Class I MHC antigens) and target antigens already present in the tumor cells. Because Class I antigens preferentially express endogenously-derived peptides to the exclusion of exogenous ones as discussed in Germain, R.N., *Nature* 322 (6081):687-689 (1986); Berzofsky, J.A. et al., *Immunol. Rev.* 106:5-31 (1988); and Grey, H.M. et al., *Sci. Am.* 261(5):56-64 (1989), they will tightly restrict the response to the desired target cells. Because this process is so markedly different from CD4⁺ T cell recognition of antigen, this experiment is devoted exclusively to an examination of CD8⁺ T cell recognition of TPO-bearing cells and the function of these cells in mediating tumor lysis.

Preliminary studies have demonstrated peripheral blood and intrathyroidal lymphocytes from cancer patients to be sensitized to TPO *in vivo*. However, to detect antigen-specific CTL, it is usually necessary to re-stimulate cells *in vitro* to induce functional CTL. In general, these studies involve the isolation of CD8⁺ T cells from thyroid cancer patients, their stimulation with various types of cells bearing different forms of TPO and a determination of the CTL activity induced by these stimulations. A major consideration is the supplementation of the growth of the CD8 cells in culture with exogenous cytokines. This is essential because CD8⁺ T cells do not produce adequate quantities of autocrine factors to support their own growth. In this regard,

different combinations of supernatant fluid from activated lymphocytes, irradiated feeder cells and specific lymphokines (such as low dose, $\leq 10 \mu\text{IU}$, recombinant IL2) is added to support the growth of these cells. Techniques for inducing large numbers of TPO antigen-specific cytotoxic T lymphocytes, either *in vitro* or *in vivo* are thus developed.

Induction of TPO-specific CD8⁺ CTL *in vitro* by TPO-bearing Thyroid Cancer Cells. A major hypothesis of this study is that thyroid cancer cells expressing TPO protein can be lysed by CTL-specific for tumor-associated TPO. The ability of these same cells to elicit this type of response prompts the investigation of the induction of a TPO-specific CTL response. Tumor cells are isolated from thyroidectomy specimens through mechanical isolation of the tumor followed by enzymatic digestion as described in Rapoport, B. et al., *Metabolism* 31:1159-1167 (1982). These cells are cultured for at least 6-8 passages *in vitro*, and the tumor cells bearing TPO are isolated with FACS or magnetic beads and anti-TPO. Approximately 1×10^5 tumor cells are co-cultured for 4-6 days with 4×10^5 CD8⁺ cells in the presence of various concentrations of IL2 and feeder cells. The CD8⁺ cells are isolated from PBMC using magnetic beads (Dynal) with either anti-CD8 (for positive selection) or anti-CD4 (for negative selection). The growth of these cells is monitored and surface markers, such as LFA-1, CD2, and other molecules involved in adhesion for cytotoxicity are identified through FACS. Other combinations of cytokines may include IL4 in place of IL2 to prevent the potential induction of non-specific LAK cells (see Kawakami, Y. et al., *Exp. Med.* 168(6):2183-2191 (1988)), or the addition of such factors as $\text{INF}\gamma$, IL-1, $\text{TNF}\alpha$ or supernatant fluid from mitogen (PHA) stimulated lymphocytes, if the initial conditions are not adequate to induce TPO-specific CTL activity.

Induction of TPO-specific CTL by Autologous Non-tumor Cells Incubated with Synthetic TPO Peptides. Although thyroid cancer cells may be very effectively lysed by CD8⁺ CTL, the tumor cells may not be appropriate cells to use to stimulate the generation of these cells. Various cytokines elaborated by tumors, such as $\text{TGF}\beta$, can inhibit the differentiation of CTL. See Wrann, M. et al., *EMBO J.* 6:1633-1636 (1987) and Ranges, G.E. et al., *J. Exp. Med.* 166(4):991-998 (1987). The presence of extraneous, non-tumor specific antigens presented aberrantly by the tumor cells may obscure the detection of an anti-TPO response. Some of the determinants from these antigens may preferentially bind to Class I antigens and block binding of TPO peptides, thereby preventing the generation of an anti-TPO response. If specific,

synthetic TPO fragments are not generated, the difficulties with using tumor cells are overcome by using normal cells that do not endogenously express TPO. Under certain circumstances extra-cellular soluble peptides can bind to Class I molecules as discussed in Townsend, A.R. et al., *Cell* 44(6):959-968 (1986). While the Class I molecules are normally occupied by cell peptides (see Bjorkman, P.J. et al., *Nature* 329(6139):506-512 (1987)), some alterations in culture conditions, such as culture at 27°C, results in the expression of Class I antigens without endogenous peptides. See Ljunggren, H.G. et al., *Nature* 346(6283):476-480 (1990) and Shumacher, T.N. et al., *Cell* 62(3):563-567 (1990). The addition of TPO peptides to these cells, especially accompanied by β -2-microglobulin as discussed in Kozlowski, S. et al., *Nature* 349(6304):74-77 (1991), may allow adequate amounts of complexes to form so that these cells can then present TPO peptides to CD8⁺ T cells. Possible cell lines used for this include autologous fibroblasts, grown from the surgical thyroidectomy specimen, or autologous EB-transformed lymphocytes. Both of these cells express Class I molecules, and since they are autologous, would share the same Class I allotype. These cells are different in that the lymphoblastoid cells can constitutively express Class I MHC while the fibroblasts do not. The effect of the differences in expression of these molecules or other differences in these cells on CTL generation is unknown, and is one parameter that can be monitored in these studies to provide important general insights into the induction of antigen-specific CTL.

The TPO peptides used to coat these cells are produced from the MBP-TPO (AA 456-933) fusion proteins. The TPO-specific areas are isolated by cleavage with Factor X α , and then are manipulated by heat denaturation, detergent or protease treatment before being added to the culture to yield peptides of TPO that will bind to the Class I MHC antigens. Truncated versions of these peptides, produced from fusion proteins like MBP-TPO 456-631, are also employed to better define the specific CD8⁺ T cell epitopes, and eventually yield a more specific and intense CTL response. If the specific epitopes are determined in this manner, synthetic peptides are then used to replace the fusion-protein derived TPO sequences.

Induction of TPO-specific CTL Activity by Cells Transformed with Viral Vectors Containing TPO cDNA. One of the advantages of having the full-length cDNA for TPO is that it can be used with a number of eukaryotic vectors to express the TPO protein in cells where this antigen is not normally found. The TPO cDNA may be placed into several vectors as described in Wilson, J.M. et al., *Science* 248(4961):1413-1416 (1990) and Shigekawa, K. et al., *Biotechniques* 6:742-751 (1988),

- 44 -

for expression in several types of autologous cells from the patients and produce cells with endogenous expression of TPO. After transformation, these cells are selected with G418, the common name referencing geneticin, as sold by Sigma Chemical, and those cells expressing large quantities are identified and isolated using FACS and
5 monoclonal anti-TPO. This results in non-thyroid cells, such as fibroblasts, over-expressing TPO, and may provide important cells for the induction of CTL. EB-lymphoblastoid cells expressing TPO have both Class I and Class II MHC antigens, and can also be used to induce both CD4⁺ and CD8⁺ anti-TPO immune responses. These cells can also provide targets to identify TPO-specific CTL activity, as control
10 cells transformed with vectors expressing irrelevant or no protein can be easily generated. Using these cells to induce CTL activity provides a unique approach resulting from a cloned and expressible tumor antigen.

Determination of Cytotoxicity against TPO Target Cells. Cytotoxicity against *in vitro* cultured thyroid cells, thyroid cancer cells or TPO gene-transfected target cells
15 is assessed using ⁵¹Cr release assay as described in Sack, J. et al., *J. Clin. Endocrinol. Metab.* 62(5):1059-1064 (1986). Thus cells are incubated with ⁵¹Cr for labeling. Excess chromium is washed off and these labelled target cells are mixed with cloned CD8⁺ T cells at various target ratios for 4 hours at 37°C, in a humidified atmosphere of 5% CO₂. Supernatant fluids are harvested and counted in a gamma
20 counter, each effector/target ratio determined in triplicate and the data presented as specific ⁵¹Cr release measured as the experimental release minus spontaneous background over the total counts present minus spontaneous background x 100, thereby giving the ratio of reactivity. The total counts releasable is determined by mixing the cells in 1% Triton x100. Spontaneous release is determined by measuring
25 the ⁵¹Cr release of the target cells cultured in media alone without cytotoxic cells. To document the MHC Class I restriction of CTL by the CD8⁺ T cell clones, blocking experiments with monoclonal antibodies against Class I or Class II antigens (as controls) are also conducted. Results are collected and analyzed to determine the specific requirements for Class I antigens necessary for TPO antigen-specific CTL.

30 **Evaluation of Molecular Elements Involved in CD8 Recognition and Binding to Tumor Cells.** Determining the exact epitopes in TPO that are recognized by the CD8⁺ T cells is of primary importance. While it might be possible to generate anti-TPO activity *in vitro* with synthetic TPO, the CD8 target epitopes must be present on the cancer cells to make cytotoxic immunity effective. Using the recombinant fusion
35 proteins and synthetic peptides described previously will allow the identification of the

specific portions of the TPO molecule recognized by the CD8 cells, and allow the determination of whether each tumor express a particular TPO epitope.

It is possible that the CTL lysis may be restricted to certain MHC Class I allotypes, either because of the inability to bind TPO peptides or the inability of the MHC-TPO peptide complex to be recognized by CD8 T cell antigen receptors. If this appears to be the case, cells from patients who appear able to present TPO peptides are tissue typed and the specific allotypes necessary to present these antigens are identified. This allows screening of patients who are most likely to respond to therapy with this antigen.

10 **Effect of TPO on Lymphokine Production by T Cell Clones.** Because of the important function lymphokines are believed to play in the induction of cytotoxic immunity to cancer cells, it is important to determine whether the T cells and T cell clones produce lymphokines in response to specific stimulation with antigen. Commercial immunoassays for TSH, IL2, IL4, IL5, IL6, TNF and interferon γ are run on
15 antigen-stimulated T cell clone supernatant fluid to determine whether or not these lymphokines are produced by the clones. Bioassays for lymphokines with more generalized actions that may mediate direct cytotoxic actions, such as TNF discussed in Filck, D.A. et al., *J. Immunol. Meth.* 68:167-175 (1984), and IL6 discussed in Ida, N. et al., *J. Immunol. Methods* 133(2):279-284 (1990), are also performed.

20 In some situations, lymphokines that are membrane bound or are delivered in local interactions between CTL and target cells may play an important role in cytotoxicity but may not be detectable in supernatant fluid. To attempt to identify these factors, the activation of transcription of the genes for IL2, IL3, IL4, IL5, IL6, interferon γ and TNF in the T cell and clones is determined using PCR techniques.
25 The PCR studies involve the cells being isolated and lysed with 100 μ l of GITC (guanidine-isothiocyanate) solution with the resulting fluid loaded onto a 100 μ l cesium chloride gradient in ultracentrifuged tubes. These tubes are spun at 80,000 RPM for 2 hours at 20°C, after which the supernatant fluid is aspirated and the pellet combined with 100 μ l of DEPC (*i.e.* diethylpyrocarbonate) treated water to resuspend the RNA.
30 Potassium acetate (10 μ l) is added to the tubes and the RNA is cold ethanol precipitated. The precipitate is then washed with 80% ethanol and the samples are air-dried. AMv reverse transcriptase will be used to produce first strand DNA from approximately 100 ng of RNA in a 50 μ l reaction at 37° for 1 hour as described in Okayama, H. et al., *Mol. Cell. Biol.* 2(2):161-170 (1982). Ten μ l of first strand cDNA
35 is mixed with 80 μ l of PCR mix (containing dNTP's mix, 200mM and Taq polymerase,

- 46 -

2.5 units per assay tube, Perkin Elmer/Cetus). Five μ l of primers for each lymphokine is added to each tube to give a final primer concentration of 1 μ M. The mixture is then subjected to PCR amplification using the Perkin-Elmer thermocycler. An ethidium bromide stained 2% agarose gel is used to separate the PCR fragments. Inclusion of a sample from a cell line known to transcribe the assayed lymphokine (e.g., Jurkat cells for IL2) is used as a positive control for each experiment. For a negative control, "mock" reverse transcription reactions are performed on RNA by omitting the reverse transcriptase enzyme and subjecting this mixture to PCR. In this way, the activation of lymphokine transcription induced by antigen is determined even in the very slight lymphokine release from the cells (on the order of μ M).

Effect of Lymphokines on Thyroid Cancer Cell Function. Assays of thyroid cell function using thyroid cancer cells in primary culture are carried out whenever adequate numbers of cells are obtained from surgical specimens. The cancer cells are cultured with supernatant fluids from CD4⁺ and CD8⁺ T cells and T cell clones. Determinations of the effect of the lymphokines include the quantitation of cAMP produced by the cancer cells as discussed in Vitti, P. et al., *J. Clin. Endocrinol. Metab.* 57 (4):782-791 (1983), and the ability to suppress thyroid cancer cell growth as measured by the induction of DNA synthesis in the measurement of ³H thymidine incorporation as described in Valente, W.A. et al., *N. Engl. J. Med.* 309 (17):1028-1034 (1983). In addition, the ability of the T cell supernatant lymphokines to suppress cancer cell production of immune-blocking factors, such as TGF β (see Lucas, C. et al., *Methods Enzymol.* 198:303-316 (1991)) and thyroglobulin (see Feldman, A. et al., *Clin. Endocrinol. (Oxf.)* 25(1):45-53 (1986)), is also assessed. Several lymphokines and cytokines have been reported to have effects on thyroid cells that may either potentiate or suppress cytotoxic actions. IL6 has been reported to suppress TPO expression in normal thyroid cells in Tomlinaga, Y. et al., *Acta Endocrinol. (Copenh.)* 124 (3):290-294 (1991), and this would be detrimental in TPO-directed cytotoxic therapy if true in cancer cells. Thus, the effects of these cytokines on thyroid cancer cells is important.

Induction of TPO Antigen-Specific TIL Cells from Thyroid Cancer. The induction of TPO-specific immune cells from TIL offers unique potentials and problems. The TIL cells have great potential for use in TPO-specific immunotherapy, as a proportion of the cells were drawn to the tumor site and their numbers expanded due to their reactivity with TPO and other tumor antigens. In addition, there is likely to be preformed CTL cells or other cells capable of mediating tumor lysis. This is supported

- 47 -

by the findings in Specific Example II, where these cells produced TNF in response to stimulation with TPO. Because of this, many of the studies outlined in this Specific Example are performed on the tumor infiltrating lymphocytes harvested from the patients thyroidectomy specimens. However, while the problems outlined in these sections certainly apply to the TIL cells, there are other considerations that make the generation of CTL from the TIL cells unique. Because this is an inflamed area, non-specific LAK and CTL activity are likely the major response, and are separated from the anti-TPO activity. This likely requires the use of different lymphokine for stimulation of antigen-specific immunity, and the cloning of all of these cells at an earlier stage of development. Also, the limited number of cells obtained from these tumors may require greater expansion of the cell populations. Thus, although similar studies are performed on the TIL cells, they require different conditions and techniques to be successful.

The differences in culture conditions for the TIL cells revolves around the initial conditions for growth, *in vitro*. The cells can be cultured as whole, enzymatic digests of thyroid tumors, purposely keeping the cancer cells present as a source of antigen and tissue dendritic cells to present antigen. Alternatively, T cells are isolated from the digested tumor through anti-T cell monoclonal antibody-labelled magnetic beads (Dynal), and cultured either with purified antigen or irradiated tumor cells in the presence of low-dose IL2 (<10 U/ml) and possibly IL4 (to inhibit the LAK activity). The cells expanded by these techniques are then evaluated as outlined above.

In Vivo Models. In addition to Hashimoto patients as human models for TPO immunotherapy, *in vivo* models of thyroid cancer are used to evaluate its efficacy. Implantation of thyroid cancer (thyroidectomy) specimens into SCID/human mice is employed because in comparison to previous models, this model will more closely replicate human disease. Since the immune cells in these thyroid glands should include a percentage of anti-TPO T cells, the immune system of the mouse provides an *in vivo* model to study immune system stimulation. Tumor regression can then be monitored as a measure of efficacy.

30 SPECIFIC EXAMPLE IV

TPO AUTOANTIBODY RESPONSES IN GRAVES' AND HASHIMOTO'S PATIENTS

Two disorders with markedly different clinical presentations, Graves' disease and Hashimoto's thyroiditis, are both associated with autoantibodies to the microsomal antigen, now identified as the enzyme thyroid peroxidase (TPO). Libert, F. et al., *EMBO J.* 6:4193-4196 (1987); Portman, L. et al., *J. Clin. Endocrinol. Metab.*

61:1001-3 (1985). Characterizing the immune response to this antigen in patients with these two diseases may help clarify differences in the pathogenesis of the autoimmune thyroid diseases (AITD) and facilitate more accurate diagnosis of thyroid disorders.

5 Recently published studies have suggested that autoantibodies directed against TPO are heterogeneous in nature. Localized autoantibody binding to a region between amino acids 590 and 675, and between amino acids 700 and 933 have been reported [Libert, F. et al., *EMBO J.* 6:4193-4196 (1987); Libert, F. et al., *J. Clin. Endocrinol. Metab.* 73:857-60 (1991); Nakajima, Y. et al., *Mol. Cell Endocrinol.* 53:15-
10 23 (1987)] and the sizes of the TPO peptide fragments examined in these studies were small enough to suggest that these epitopes were not conformational. Several other reports using purified native TPO have suggested that there may be multiple autoantibody epitopes, some of which are conformational. Doble, N.D. et al., *Immunology* 64:23-29 (1988); Yokoyama, N. et al., *J. Clin. Endocrinol. Metab.* 70:758-
15 65 (1990); Finke, R. et al., *J. Clin. Endocrinol. Metab.* 73:919-21 (1991). Previous work has demonstrated localized autoantibody epitopes in the portion of the human TPO molecule from amino acids 456 to 933, and suggested the presence of multiple binding sites. See Maastricht, J. et al., *J. Clin. Endocrinol. Metab.* 75:121-26 (1992).

20 In the present invention, the serologic immune response to native thyroid microsomal antigen, denatured and reduced microsomal antigen, and several recombinant peptide fragments of human TPO in patients with Graves' disease and Hashimoto's thyroiditis was characterized. The results were then correlated to measures of clinical disease activity in order to determine if clinical subgroups or associations related to specific types of anti-TPO activity.

25 **Overview.** In order to examine the specificity of the autoantibody response to thyroid peroxidase in autoimmune thyroid disease, the reactivity of sera from 45 Hashimoto's and 48 Graves' patients to native thyroid microsome, denatured and reduced human TPO and several recombinant fragments of human TPO corresponding to amino acids 457-933 of the native protein were examined. Both
30 Graves' and Hashimoto's sera bound native, denatured and reduced TPO at significantly greater rates than normal controls, and no differences were noted between the two disorders in binding to these forms of the autoantigen. Binding was also noted to two recombinant fragments of TPO, corresponding to amino acids 513-633 and 633-933 in TPO. The frequency of autoantibodies to the TPO(633-933) region
35 was not significantly different in Hashimoto's vs. Graves' disease patients (58% vs.

65% respectively), and appeared to relate to evidence of glandular inflammation in the Graves' patients (goiter, presence of anti-thyroglobulin antibodies and elevated FT3 levels). In contrast, antibodies to the TPO(AA 513-633) fragment were significantly more common in Hashimoto's vs. Graves' disease patients (53% vs. 23% respectively), and did not correlate with any measure of glandular inflammation. These results identify two specific regions of TPO autoantibody binding and indicate that there are differences in the autoantibody response to TPO in Hashimoto's and Graves' diseases.

Materials and Methods

10 **Patient Sera.** Forty-five patients with Hashimoto's disease, forty-eight patients with Graves' disease and twenty-five age and gender-matched normal controls were enrolled in the study. The Hashimoto's patients were diagnosed on the basis of anti-microsomal antibody titers of greater than or equal to 1:400 by agglutination assay in the presence of either goiter or hypothyroidism. The age of the patients ranged from 15 12 to 77 years. The Graves' patients were diagnosed on the basis of clinical and biochemical evidence of hyperthyroidism (suppressed TSH with elevated T4), diffuse goiter and an increased 24 hour radiiodine uptake. None of the controls had clinical evidence or a past history of thyroid disease. Sera were obtained at the time of enrollment, and frozen at -70° until use.

20 **Construction Of TPO Expression Plasmids.** The plasmid pMaITPO(457-933) was developed from pMalcRI (New England Biolabs) and contains (in-frame) the cDNA coding for TPO AA 457-933, as has been previously reported. Maastricht, J. et al, *J. Clin. Endocrinol. Metab.* 75:121-26 (1992). This construct encodes a fusion protein in which the amino terminal portion is maltose binding protein minus its leader sequence, followed first by the sequence IEGRISEF (one letter amino acid code), then the fragment of human TPO. This vector was used to make several new constructs containing fragments of the coding region of the human TPO cDNA from amino acids 457-933. The plasmid pMaITPO(457-633) was developed by digestion of pMaITPO(457-933) with ClaI and XbaI. The linearized plasmid was separated from the 25 excised fragment by agarose gel electrophoresis and the plasmid was ligated to the adapter 5'-CGATTAGGTAGGTAGT (top strand), which recreates the ClaI and XbaI sites and inserts a stop codon after amino acid 633. The plasmid pMaITPO(633-933) was developed by digestion of pMaITPO(AA 457-933) with EcoRI and ClaI with the deletion of the excised fragment followed by Klenow fill-in and religation. The plasmid 30 pMaITPO(AA 513-633) was created by digestion of pMaITPO(AA 457-633) with EcoRI

- 50 -

and SmaI followed by ligation to the adapter 5'-AATTCGACCTGCCC (top strand). The plasmid pMalTPO(AA 457-517) was created by digestion of pMalTPO(AA 457-633) with SmaI and XbaI, isolation of the linearized plasmid and ligation to the oligonucleotide adapter 5'-GGGCTGTAGT (top strand). Each construct was confirmed by restriction digestion and DNA sequencing of the 5' ligation junction.

Expression and Purification of Fusion Proteins. The plasmid constructs were used to transform *E. coli* HB 101, grown, harvested, lysed, and sonicated as previously described in the art. Maastricht, J. et al., *J. Clin. Endocrinol. Metab.* 75:121-26 (1992). The lysate was run over an amylose affinity column to isolate the MBP fusion proteins in accordance with the vendor's protocol, and the fusion proteins were then eluted using column buffer with 10 mM Maltose.

Preparation of Thyroid Microsomal Antigen. Human microsomal antigen was isolated from normal human thyroid tissue obtained under informed consent from thyroidectomy samples as previously reported in the art. Finke, R. et al., *J. Clin. Endocrinol. Metab.* 73:919-21 (1991).

SDS-PAGE and Western Blots. Thyroid microsomal antigen or MBP-TPO fusion proteins were diluted with buffer consisting of 0.125 M Tris pH 6.8 with 4% SDS and 20% glycerol to a concentration of approximately 3 mg/ml. Approximately 500 μ l of this solution was loaded into a single preparative well and electrophoresed through an 8% SDS Polyacrylamide gel. For the reducing gels and in all of the MBP-TPO samples, 10% β -mercaptoethanol was added to the sample buffer, and the samples were boiled for 5 minutes before electrophoresis. After electrophoresis, proteins were electro-transferred to nitrocellulose membranes, and these membranes were then blocked with 3% BSA in PBS for two hours at 27°C. Western blots were then performed using a 1:400 dilution of patient sera in PBS with 1% BSA and 0.01% sodium azide. Maastricht, J. et al., *J. Clin. Endocrinol. Metab.* 75:121-26 (1992). For the blots using the fusion protein, the sera were pre-incubated for 3 hours with maltose binding protein-LacZ fusion proteins (0.1 mg/ml) to block any potential reactivity to the maltose binding protein portion of the TPO fusion proteins. Controls included a monoclonal antibodies to thyroid peroxidase and MBP to identify the TPO-specific and MBP-specific bands. Ten patients with high titer anti-nuclear antibodies (ANA>1:6400) randomly selected from the clinical laboratory were also evaluated in the Western blot assays to determine the disease specificity of TPO autoantibodies.

Clinical Measurements. Thyroid function tests (including FT4, FT3, TSH) and thyroglobulin and thyroid microsomal antibody titers were performed on either

- 51 -

identical serum samples used for Western blots or repeat samples drawn within 2 months of the original sample. The thyroid functions were performed in a routine clinical laboratory, while the TSH levels were determined by a sensitive, second generation fluorescence immunoassay. Thyroglobulin and microsomal antibody titers
5 were determined by agglutination assay (Ames Diagnostics, Ames, IA). Goiter size and degree of ophthalmopathy were determined by an individual who was unaware of the TPO reactivity of the subjects.

Statistical Analyses. The rates of reactivity to different areas of TPO in the Graves' and Hashimoto's disease patients, and the normal subjects were compared
10 by Fisher's exact test. The continuous variables were compared by using ANOVA.

Results

Reactivity to Denatured and Reduced TPO. As previously reported (Hamada, N. et al, *J. Clin. Invest.* 79:819-25 (1987)), a band of approximately 220 kDa in immunoblots was identified as the non-reduced form of TPO. Under reducing
15 conditions, antibodies against TPO identified three bands ranging from 100 - 105 kDa. Similar patterns of reactivity to these bands was noted in both the Hashimoto's and Graves' patients. As shown in Table 1, the frequency of reactivity of the Hashimoto's and Graves' sera were statistically identical to each other, but markedly greater than that of the control sera.

20

Table 1

TPO Form	Normal Controls	Graves' Disease	Hashimoto's Disease
Denatured TPO	3/21 (14%)	40/48 (83%) *	34/45 (76%) *
Reduced TPO	1/21 (5%)	23/48 (48%) *	27/45 (60%) *
TPO (513-633)	1/25 (4%)	11/48 (23%) *	24/45 (53%) *‡
TPO (633-933)	2/25 (8%)	31/48 (64%) *	26/45 (58%) *
Both Fragments	0/25 (0%)	9/48 (19%) *	12/45 (27%) *
Either Fragment	2/25 (8%)	33/48 (69%) *	38/45 (84%) *

*P<0.05 vs. Normals

‡P<0.01 vs. Graves'

Autoantibodies against the TPO Fragments. Initial studies failed to demonstrate serologic reactivity with the fragment TPO(AA 457-517) in any of the patient sera, while immunoblots done with either TPO(AA 457-633) or (AA 513-633) showed identical patterns of reactivity. Therefore, the TPO(AA 513-633) region was presumed to contain the autoantibody binding site between amino acids 457-633. Of the 45 Hashimoto's patients studied, 24 (53%) showed reactivity to TPO(AA 513-633), while in the Graves' group, only 11 of the 48 patients (23%) reacted to this region.

Figures 17A and 17B are representative Western blots demonstrating autoantibody reactivity to recombinant TPO (AA 513-633). Sera from Hashimoto's patients (Panel A) and from Graves' patients (Panel B) showed intense reactivity with the fusion protein at 56 kDa (arrow). Control (+) is an anti-MBP antiserum used to identify the location of the fusion protein (arrow). Blots using a control MBP fusion protein indicated no patient binding (data not shown). As shown in Table 1, this difference was highly significant. Only one of the normal controls reacted to TPO(AA 513-633), and the blot showed minimal intensity. In contrast, the frequency of autoantibody reactivity to TPO(AA 633-933) was similar in both the Hashimoto's and Graves' patients. Also, there was no significant difference in reactivity to TPO(AA 513-633) based on whether the patient recognized denatured and reduced TPO, while the TPO(AA 633-933) fragment was recognized at significantly higher rates in patients

- 53 -

reactive to denatured/reduced TPO ($p < 0.05$). This suggests an association between autoantibody binding to denatured and reduced TPO and antibodies to the TPO(AA 633-933) region which is not seen with antibodies to the TPO(513-633) region. Of interest, the microsomal antibody titer (as determined by the agglutination assay) did not correlate with binding to either region of TPO or reduced TPO by Western blot in either patient group. Also, none of the 10 control patients with SLE bound to either fragment, suggesting these autoantibodies were disease-specific.

Clinical Correlation with TPO Reactivity. For the Hashimoto's patients, there was no significant correlation between any of the clinical parameters (age, goiter size, anti-microsomal antibody titers and anti-thyroglobulin antibody titers (by agglutination assay) or hypothyroidism) and reactivity to either the recombinant fragments, or the reduced or non-reduced forms of TPO. In the Graves' patients, no statistically significant correlation was seen between age, FT4, ^{131}I uptake, or antimicrosomal antibodies and reactivity to the two regions of TPO or to the reduced and denatured forms of TPO. Correlations were noted between reactivity to reduced TPO and the following parameters in Graves' patients; the presence of anti-thyroglobulin antibody titers ($P=0.04$), with higher levels of FT3 ($P=0.001$) and larger goiters ($P=0.04$). There was no correlation between the presence of ophthalmopathy and reactivity to any portion of TPO. The cDNA for human TPO used for the initial MBP construct was a gracious gift of Dr. Basil Rapoport and has been accorded GenBank Accession Number J02969.

Discussion

These results indicate that the autoantibody response to TPO is truly heterogeneous and that there are at least two localized areas in TPO that are recognized by autoantibodies from a majority of patients with AITD. The recognition of one of the areas, corresponding to amino acids 513-633, was more frequently seen in Hashimoto's disease than Graves' disease. Sera from patients with Hashimoto's disease were equally likely to be reactive to TPO(AA 513-633) and TPO(AA 633-933) while, amongst the Graves' patients, the frequency of reactivity to TPO(AA 633-933) was 3 times higher than to TPO(AA 513-633). This difference did not appear to be the result of differences in the overall serologic response to TPO, as there was no difference between the two disorders in the titer of antibodies to anti-microsomal antigen (by agglutination assay) or reduced and denatured TPO (by Western blot). Thus, the present invention shows that autoantibodies against TPO amino acids 513-

633 are observed more often in Hashimoto's thyroiditis patients as compared to Graves' disease patients.

Specific Example IV of the present invention is thus in direct contrast to the findings of Zanelli, which shows autoantibody binding to all portions of TPO with no difference between Graves' and Hashimoto's patients. (Zanelli, E. et al., *Clin. Exp. Immunol.* 87:80-86 (1992)) Note, that the Western blots in Zanelli's studies used sera at a high concentration (1:25 dilution) and did not compare patient binding to normal controls. Therefore, it is difficult to determine if Zanelli (and colleagues) identified autoantibodies specific for autoimmune thyroid disease.

10 The reason for the association of autoantibodies to the TPO(AA 513-633) with Hashimoto's disease is not clear. It has been speculated that antibodies to localized or sequential autoantigen epitopes are a consequence of denaturation and unfolding of autoantigens. Laver, W.G. et al., *Cell* 61:553-56 (1990). Inflammation of the thyroid gland unique to Hashimoto's disease might result in the denaturation of TPO, which
15 would then result in antibodies to TPO(AA 513-633). However, the reactivity to TPO(AA 633-933) region and to reduced and denatured TPO was not different between Graves' and Hashimoto's patients. In addition, unlike autoantibodies to TPO(AA 633-933), antibodies to the TPO(AA 513-633) fragment did not correlate with serologic reactivity to denatured TPO in the Hashimoto's patients. Therefore, the
20 differences in the rates of reactivity to TPO(AA 513-633) cannot be explained solely as the consequence of an inflammatory process that yields autoantibodies to denatured TPO.

In arguing a pathogenic role for TPO autoantibodies, several studies have shown that anti-microsomal antibodies from patients with Hashimoto's disease have
25 been shown to inhibit the activity of TPO. Okamoto, Y. et al., *J. Clin. Endocrinol Metab.* 68:730-34 (1989). The TPO(AA 513-633) fragment overlaps with a region, amino acids 510 to 567, previously reported to show homology to the heme binding site of the Cytochrome C oxidase enzyme (Libert, F. et al., *EMBO J.* 6:4193-4196 (1987)) and therefore may constitute a functional part of the enzyme. The different
30 reactivity to TPO(AA 513-633) suggests a possible pathophysiologic role for TPO antibodies in Hashimoto's disease and could also explain the variability in the studies examining the effect of autoantibodies on TPO function. However, there appeared to be no significant correlation between reactivity to any form or region of TPO and any clinical characteristic of the Hashimoto's patients. While this could be due to
35 variations in the clinical presentation of Hashimoto's disease and the fact that serum

- 55 -

samples were obtained from the patients at variable times during the course of the disease, it might indicate that TPO autoantibodies do not play a prominent role in the producing clinical signs of AITD (e.g., hypothyroidism or goiter size). To resolve this question, reactivity to this region might be evaluated in a prospective manner in
5 relatives of Hashimoto's patients to see if these autoantibodies presage the development of thyroiditis. In the Graves' patients, a significant correlation was noted between the goiter, anti-thyroglobulin antibody titers and reactivity to both TPO(AA 633-933) and the reduced form of TPO. This may indicate that antibodies to this area of TPO are a marker for glandular inflammation in Graves' disease.

10 Since Western blot assays are not as sensitive as other immunoassays, and may underestimate the number of reactive patients, there may be more than one epitope in the TPO(AA 513-633) region, only one of which is specific for Hashimoto's disease. In addition, while some of the Graves' patients did react to this area, it is possible that these patients may have concomitant Hashimoto's disease. The
15 coexistence of these diseases is well-documented (Hirota, Y. et al., *J. Clin. Endocrinol. Metab.* 62:165-69 (1986)), and the identification of this patient subgroup may be of value because these individuals might develop long-term remissions of their hyperthyroidism due to the presence of the thyroiditis. However, since all of the Graves' patients in this study were treated with thyroid ablation, this hypothesis was
20 not tested.

SPECIFIC EXAMPLE V

EPITOPE MAPPING OF THE TPO 592-613 AUTOANTIBODY BINDING SITE

In order to further localize and understand the specificity of autoantibodies binding to thyroid peroxidase, efforts were undertaken to determine the exact epitopes
25 of TPO autoantibodies directed to the fragment of TPO contained within amino acids. Initially, the AA 517-633 fragment was digested with an additional restriction enzyme to yield a AA 573-633 fragment. This portion of TPO retained the binding activity present in the whole AA 517-633 fragment. However, it became apparent that there were no appropriate restriction enzyme sites to further cut the cDNA. Thus, for fine
30 mapping of this autoantibody binding site, the polymerase chain reaction (PCR) was used.

Figure 18 is a schematic of the fine mapping of the TPO epitope using PCR. Primers were constructed to amplify cDNA segments of approximately 60 nucleotides (20 amino acids) in length. The initial (smallest fragment) was between amino acids
35 592-613 (20 amino acids from the ends of the 573-633 fragment). The primers were

also prepared with the appropriate restriction enzyme sites at either end for insertion into the pMalc expression plasmid. The fragment of the cDNA corresponding to the intervening segment between these primers was amplified, ethanol precipitated and digested with the appropriate restriction enzyme. The cDNA products were then
5 subjected to PAGE, isolated from the gel and used to ligate appropriately digested pMalc vector. This vector was then used to transform bacteria, and protein production was induced with IPTG. A fusion protein corresponding to the area of TPO encompassed by the primers was then isolated through amylose affinity chromatography. The work was conducted in a manner similar to that described in
10 Specific Example I and Maastricht, J. et al. *J. Clin. Endocrinol. Metab.* 75:121-126 (1992).

Western blots of the 596-611 fusion protein (performed by the protocol set forth above in Specific Example IV), showed that this fusion protein did not contain the epitope, and new primers were used which added four amino acids at either end to
15 produce the region 590-615. Western blots with the resulting fusion protein showed that the AA 590-615 region was recognized by autoantibodies, and could inhibit binding to the whole AA 517-633 fragment. In cross-amplification experiments, it was shown that the 592-615 fragment maintained the epitope whereas the 590-611 fragment did not, thereby documenting that the carboxyl limit of the binding site was
20 located between amino acids 611 and 615. Subsequent amplification showed that if the peptide C-terminus was at an amino acid less than 613, the binding was lost. Together, this localized the epitope binding site between amino acids 592 and 613.

Discussion

The localized binding site between AA 592 and 613 is unique in that it shows
25 strong immunology between the other peroxidase enzymes (myeloperoxidase and lactoperoxidase) with divergent sequences primarily between amino acids 602 and 615. In addition, it is almost entirely homologous between human, porcine and rat TPO with only two non-conserved substitutions within the whole coding region. Thus, it appears that this segment is unique for thyroid peroxidase and does not share
30 sufficient immunology with any of the other peroxidase enzymes to account for cross reactivity. Binding studies with myeloperoxidase and lactoperoxidase also fail to show binding activity in antibodies affinity purified using AA 590-615 peptides. Previously, antibodies against thyroid peroxidase have been shown to cross-react with these two other enzymes, thereby confusing diagnosis. The present invention, however,
35 specifies a region containing an autoantibody epitope that is unique and specific for

- 57 -

thyroid peroxidase. Having now defined this epitope to 22 amino acids, it can be manufactured synthetically and provide specificity in the diagnosis of autoantibodies to thyroid peroxidase and Hashimoto's disease and for use in immunotherapy.

Those skilled in the art can appreciate from the foregoing description that the
5 broad teachings of the present invention can be implemented in a variety of forms. Therefore, while this invention has been described in connection with particular examples thereof, the true scope of the invention should not be so limited since other modifications will become apparent upon a study of the drawings, specification and following claims. All applications and publications cited herein are incorporated by
10 reference. It will be appreciated that the publications cited herein merely reflect the current state of the art and the skills and methodology attendant to those skilled in the art.

- 58 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Baker, Jr., James R.
Koenig, Ronald J.

(ii) TITLE OF INVENTION: Thyroid Peroxidase Epitopic Regions

(iii) NUMBER OF SEQUENCES: 2

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Harness, Dickey & Pierce

(B) STREET: P.O. Box 828

(C) CITY: Bloomfield Hills

(D) STATE: MI

(E) COUNTRY: USA

(F) ZIP: 48303

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

- 59 -

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: Lewak, Anna M.
- (B) REGISTRATION NUMBER: 33006
- (C) REFERENCE/DOCKET NUMBER: 2115-00658PPA

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: (313) 641-1600
- (B) TELEFAX: (313) 641-0270

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 933 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: N-terminal

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens
- (D) DEVELOPMENTAL STAGE: Mature
- (F) TISSUE TYPE: Thyroid gland (from people with Grave's disease)

(vii) IMMEDIATE SOURCE:

- (B) CLONE: phTPO-2.8

(x) PUBLICATION INFORMATION:

- (A) AUTHORS: Kimura, S.
Kotani, T.
McBride, O. W.

- 60 -

Umeki, K.
Nakayama, T.
Ohtaki, S.
Hirai, K.

(B) TITLE: Human thyroid peroxidase: Complete cDNA and protein sequence, chromosome mapping, and identification of two alternately spliced mRNAs

(C) JOURNAL: Proc. Natl. Acad. Sci. U.S.A.

(D) VOLUME: 84

(F) PAGES: 5555-5559

(G) DATE: 1987

(K) RELEVANT RESIDUES IN SEQ ID NO:1: FROM 1 TO 3048

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Met	Arg	Ala	Leu	Ala	Val	Leu	Ser	Val	Thr	Leu	Val	Met	Ala	Cys	Thr
1			5						10					15	
Glu	Ala	Phe	Phe	Pro	Phe	Ile	Ser	Arg	Gly	Lys	Glu	Leu	Leu	Trp	Gly
		20					25					30			
Lys	Pro	Glu	Glu	Ser	Arg	Val	Ser	Ser	Val	Leu	Glu	Glu	Ser	Lys	Arg
		35					40					45			
Leu	Val	Asp	Thr	Ala	Met	Tyr	Ala	Thr	Met	Gln	Arg	Asn	Leu	Lys	Lys
	50					55				60					
Arg	Gly	Ile	Leu	Ser	Pro	Ala	Gln	Leu	Leu	Ser	Phe	Ser	Lys	Leu	Pro
65					70					75					80
Glu	Pro	Thr	Ser	Gly	Val	Ile	Ala	Arg	Ala	Ala	Glu	Ile	Met	Glu	Thr
			85					90					95		
Ser	Ile	Gln	Ala	Met	Lys	Arg	Lys	Val	Asn	Leu	Lys	Thr	Gln	Gln	Ser
		100						105					110		
Gln	His	Pro	Thr	Asp	Ala	Leu	Ser	Glu	Asp	Leu	Leu	Ser	Ile	Ile	Ala
		115					120					125			
Asn	Met	Ser	Gly	Cys	Leu	Pro	Tyr	Met	Leu	Pro	Pro	Lys	Cys	Pro	Asn
	130					135					140				
Thr	Cys	Leu	Ala	Asn	Lys	Tyr	Arg	Pro	Ile	Thr	Gly	Ala	Cys	Asn	Asn
145				150						155					160
Arg	Asp	His	Pro	Arg	Trp	Gly	Ala	Ser	Asn	Thr	Ala	Leu	Ala	Arg	Trp
			165						170						175

- 61 -

Leu Pro Pro Val Tyr Glu Asp Gly Phe Ser Gln Pro Arg Gly Trp Asn
 180 185 190
 Pro Gly Phe Leu Tyr Asn Gly Phe Pro Leu Pro Pro Val Arg Glu Val
 195 200 205
 Thr Arg His Val Ile Gln Val Ser Asn Glu Val Val Thr Asp Asp Asp
 210 215 220
 Arg Tyr Ser Asp Leu Leu Met Ala Trp Gly Gln Tyr Ile Asp His Asp
 225 230 235 240
 Ile Ala Phe Thr Pro Gln Ser Thr Ser Lys Ala Ala Phe Gly Gly Gly
 245 250 255
 Ala Asp Cys Gln Met Thr Cys Glu Asn Gln Asn Pro Cys Phe Pro Ile
 260 265 270
 Gln Leu Pro Glu Glu Ala Arg Pro Ala Ala Gly Thr Ala Cys Leu Pro
 275 280 285
 Phe Tyr Arg Ser Ser Ala Ala Cys Gly Thr Gly Asp Gln Gly Ala Leu
 290 295 300
 Phe Gly Asn Leu Ser Thr Ala Asn Pro Arg Gln Gln Met Asn Gly Leu
 305 310 315 320
 Thr Ser Phe Leu Asp Ala Ser Thr Val Tyr Gly Ser Ser Pro Ala Leu
 325 330 335
 Glu Arg Gln Leu Arg Asn Trp Thr Ser Ala Glu Gly Leu Leu Arg Val
 340 345 350
 His Ala Arg Leu Arg Asp Ser Gly Arg Ala Tyr Leu Pro Phe Val Pro
 355 360 365
 Pro Arg Arg Pro Ala Ala Cys Ala Pro Glu Pro Gly Ile Pro Gly Glu
 370 375 380
 Thr Arg Gly Pro Cys Phe Leu Ala Gly Asp Gly Arg Ala Ser Glu Val
 385 390 395 400
 Pro Ser Leu Thr Ala Leu His Thr Leu Trp Leu Arg Glu His Asn Arg
 405 410 415
 Leu Ala Ala Ala Leu Lys Ala Leu Asn Ala His Trp Ser Ala Asp Ala
 420 425 430
 Val Tyr Gln Glu Ala Arg Lys Val Val Gly Ala Leu His Gln Ile Ile
 435 440 445
 Thr Leu Arg Asp Tyr Ile Pro Arg Ile Leu Gly Pro Glu Ala Phe Gln
 450 455 460

- 62 -

Gln Tyr Val Gly Pro Tyr Glu Gly Tyr Asp Ser Thr Ala Asn Pro Thr
 465 470 475 480
 Val Ser Asn Val Phe Ser Thr Ala Ala Phe Arg Phe Gly His Ala Thr
 485 490 495
 Ile His Pro Leu Val Arg Arg Leu Asp Ala Ser Phe Gln Glu His Pro
 500 505 510
 Asp Leu Pro Gly Leu Trp Leu His Gln Ala Phe Phe Ser Pro Trp Thr
 515 520 525
 Leu Leu Arg Gly Gly Gly Leu Asp Pro Leu Ile Arg Gly Leu Leu Ala
 530 535 540
 Arg Pro Ala Lys Leu Gln Val Gln Asp Gln Leu Met Asn Glu Glu Leu
 545 550 555 560
 Thr Glu Arg Leu Phe Val Leu Ser Asn Ser Ser Thr Leu Asp Leu Ala
 565 570 575
 Ser Ile Asn Leu Gln Arg Gly Arg Asp His Gly Leu Pro Gly Tyr Asn
 580 585 590
 Glu Trp Arg Glu Phe Cys Gly Leu Pro Arg Leu Glu Thr Pro Ala Asp
 595 600 605
 Leu Ser Thr Ala Ile Ala Ser Arg Ser Val Ala Asp Lys Ile Leu Asp
 610 615 620
 Leu Tyr Lys His Pro Asp Asn Ile Asp Val Trp Leu Gly Gly Leu Ala
 625 630 635 640
 Glu Asn Phe Leu Pro Arg Ala Arg Thr Gly Pro Leu Phe Ala Cys Leu
 645 650 655
 Ile Gly Lys Gln Met Lys Ala Leu Arg Asp Gly Asp Trp Phe Trp Trp
 660 665 670
 Glu Asn Ser His Val Phe Thr Asp Ala Gln Arg Arg Glu Leu Glu Lys
 675 680 685
 His Ser Leu Ser Arg Val Ile Cys Asp Asn Thr Gly Leu Thr Arg Val
 690 695 700
 Pro Met Asp Ala Phe Gln Val Gly Lys Phe Pro Glu Asp Phe Glu Ser
 705 710 715 720
 Cys Asp Ser Ile Pro Gly Met Asn Leu Glu Ala Trp Arg Glu Thr Phe
 725 730 735
 Pro Gln Asp Asp Lys Cys Gly Phe Pro Glu Ser Val Glu Asn Gly Asp
 740 745 750

- 63 -

Phe Val His Cys Glu Glu Ser Gly Arg Arg Val Leu Val Tyr Ser Cys
 755 760 765
 Arg His Gly Tyr Glu Leu Gln Gly Arg Glu Gln Leu Thr Cys Thr Gln
 770 775 780
 Glu Gly Trp Asp Phe Gln Pro Pro Leu Cys Lys Asp Val Asn Glu Cys
 785 790 795 800
 Ala Asp Gly Ala His Pro Pro Cys His Ala Ser Ala Arg Cys Arg Asn
 805 810 815
 Thr Lys Gly Gly Phe Gln Cys Leu Cys Ala Asp Pro Tyr Glu Leu Gly
 820 825 830
 Asp Asp Gly Arg Thr Cys Val Asp Ser Gly Arg Leu Pro Arg Ala Thr
 835 840 845
 Trp Ile Ser Met Ser Leu Ala Ala Leu Leu Ile Gly Gly Phe Ala Gly
 850 855 860
 Leu Thr Ser Thr Val Ile Cys Arg Trp Thr Arg Thr Gly Thr Lys Ser
 865 870 875 880
 Thr Leu Pro Ile Ser Glu Thr Gly Gly Gly Thr Pro Glu Leu Arg Cys
 885 890 895
 Gly Lys His Gln Ala Val Gly Thr Ser Pro Gln Arg Ala Ala Ala Gln
 900 905 910
 Asp Ser Glu Gln Glu Ser Ala Gly Met Glu Gly Arg Asp Thr His Arg
 915 920 925
 Leu Pro Arg Ala Leu
 930

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3048 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: mRNA

(iii) HYPOTHETICAL: NO

- 64 -

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(D) DEVELOPMENTAL STAGE: Mature

(F) TISSUE TYPE: Thyroid gland (from patients with
Grave's disease)

(vii) IMMEDIATE SOURCE:

(B) CLONE: phTPO-2.8

(viii) POSITION IN GENOME:

(A) CHROMOSOME/SEGMENT: 2pter-q11

(x) PUBLICATION INFORMATION:

(A) AUTHORS: Kimura, S.
Kotani, T.
McBride, O. W.
Umeki, K.
Nakayama, T.
Ohtaki, S.
Hirai, K.(B) TITLE: Human thyroid peroxidase: Complete cDNA and
protein sequence, chromosome mapping, and
identification of two alternately spliced mRNAs

(C) JOURNAL: Proc. Natl. Acad. Sci. U.S.A.

(D) VOLUME: 84

(F) PAGES: 5555-5559

(G) DATE: 1987

(K) RELEVANT RESIDUES IN SEQ ID NO:2: FROM 1 TO 3048

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CATTTCAGAA GAGTTACAGC CGTGAAAATT ACTCAGCAGT GCAGTTGGCT GAGAAGAGGA
60AAAAAGGTCA GAATGAGAGC GCTCGCTGTG CTGTCTGTCA CGCTGGTTAT GGCCTGCACA
120

- 65 -

GAAGCCTTCT TCCCCTTCAT CTCGAGAGGG AAAGAACTCC TTTGGGGAAA GCCTGAGGAG
180

TCTCGTGTCT CTAGCGTCTT GGAGGAAAGC AAGCGCCTGG TGGACACCGC CATGTACGCC
240

ACGATGCAGA GAAACCTCAA GAAAAGAGGA ATCCTTTCTC CAGCTCAGCT TCTGTCTTTT
300

TCCAAACTTC CTGAGCCAAC AAGCGGAGTG ATTGCCCGAG CAGCAGAGAT AATGGAAACA
360

TCAATACAAG CGATGAAAAG AAAAGTCAAC CTGAAAAC TC AACATCACA GCATCCAACG
420

GATGCTTTAT CAGAAGATCT GCTGAGCATC ATTGCAAACA TGTCTGGATG TCTCCCTTAC
480

ATGCTGCCCC CAAAATGCCC AAACACTTGC CTGGCGAACA AATACAGGCC CATCACAGGA
540

GCTTGCAACA ACAGAGACCA CCCAGATGG GGC GCCTCCA ACACGGCCCT GGCACGATGG
600

CTCCCTCCAG TCTATGAGGA CGGCTTCAGT CAGCCCCGAG GCTGGAACCC CGGCTTCTTG
660

TACAACGGGT TCCCACTGCC CCCGGTCCGG GAGGTGACAA GACATGTCAT TCAAGTTTCA
720

AATGAGGTTG TCACAGATGA TGACCGCTAT TCTGACCTCC TGATGGCATG GGGACAATAC
780

ATCGACCAG ACATCGCGTT CACACCACAG AGCACCAGCA AAGCTGCCTT CGGGGGAGGG
840

GCTGACTGCC AGATGACTTG TGAGAACCAA AACCCATGTT TTCCCATACA ACTCCCGGAG
900

GAGGCCCGGC CGGCCGCGGG CACCGCCTGT CTGCCCTTCT ACCGCTCTTC GGCCGCCTGC
960

GGCACCAGGG ACCAAGGCGC GCTCTTTGGG AACCTGTCCA CGGCCAACCC GCGGCAGCAG
1020

ATGAACGGGT TGACCTCGTT CCTGGACGCG TCCACCGTGT ATGGCAGCTC CCCGGCCCTA
1080

GAGAGGCAGC TGC GGAAGT GACCAAGTGC GAAGGGCTGC TCCGCGTCCA CGCGCGCCTC
1140

CGGGACTCCG GCCGCGCCTA CCTGCCCTTC GTGCCGCCAC GCGGCCTGC GGCCTGTGCG
1200

- 66 -

CCCGAGCCCG GCATCCCCGG AGAGACCCGC GGGCCCTGCT TCCTGGCCGG AGACGGCCGC
1260

GCCAGCGAGG TCCCCTCCCT GACGGCACTG CACACGCTGT GGCTGCGCGA GCACAACCGC
1320

CTGGCCGCGG CGCTCAAGGC CCTCAATGCG CACTGGAGCG CGGACGCCGT GTACCAGGAG
1380

GCGCGCAAGG TCGTGGGCGC TCTGCACCAG ATCATCACCC TGAGGGATTA CATCCCCAGG
1440

ATCCTGGGAC CCGAGGCCTT CCAGCAGTAC GTGGGTCCCT ATGAAGGCTA TGA CTCCACC
1500

GCCAACCCCA CTGTGTCAA CGTGTCTCC ACAGCCGCCT TCCGCTTCGG CCATGCCACG
1560

ATCCACCCGC TGGTGAGGAG GCTGGACGCC AGCTTCCAGG AGCACCCGA CCTGCCCCGG
1620

CTGTGGCTGC ACCAGGCTTT CTTAGCCCA TGGACATTAC TCCGTGGAGG TGGTTTGGAC
1680

CCACTAATAC GAGGCCTTCT TGCAAGACCA GCCAACTGC AGGTGCAGGA TCAGCTGATG
1740

AACGAGGAGC TGACGGAAAG GCTCTTTGTG CTGTCCAATT CCAGCACCTT GGATCTGGCG
1800

TCCATCAACC TGCAGAGGGG CCGGGACCAC GGGCTGCCAG GTTACAATGA GTGGAGGGAG
1860

TTCTGCGGCC TGCCTCGCCT GGAGACCCCC GCTGACCTGA GCACAGCCAT CGCCAGCAGG
1920

AGCGTGCCCG ACAAGATCCT GGA CTGTGAC AAGCATCCTG ACAACATCGA TGTCTGGCTG
1980

GGAGGCTTAG CTGAAA CTCTCC CAGG GCTCGGACAG GGCCCTGTT TGCCTGTCTC
2040

ATTGGGAAGC AGATGAAGGC TCTGCGGGAT GGTGACTGGT TTTGGTGGGA GAACAGCCAC
2100

GTCTTCACGG ATGCACAGAG GCGTGAGCTG GAGAAGCACT CCCTGTCTCG GGT CATCTGT
2160

GACAACACTG GCCTCACCAG GGTGCCCATG GATGCCTTCC AAGTCGGCAA ATTCCCTGAA
2220

GACTTTGAGT CTTGTGACAG CATCCCTGGC ATGAACCTGG AGGCCTGGAG GGAAACCTTT
2280

- 67 -

CCTCAAGACG ACAAGTGTGG CTTCCCAGAG AGCGTGGAGA ATGGGGACTT TGTGCACTGT
2340

GAGGAGTCTG GGAGGCGCGT GCTGGTGTAT TCCTGCCGGC ACGGGTATGA GCTCCAAGGC
2400

CGGGAGCAGC TCACTTGCAC CCAGGAAGGA TGGGATTTCC AGCCTCCCCT CTGCAAAGAT
2460

GTGAACGAGT GTGCAGACGG TGCCACCCCC CCCTGCCACG CCTCTGCGAG GTGCAGAAAC
2520

ACCAAAGGCG GCTTCCAGTG TCTCTGCGCG GACCCCTACG AGTTAGGAGA CGATGGGAGA
2580

ACCTGCGTAG ACTCCGGGAG GCTCCCTCGG GCGACTTGA TCTCCATGTC GCTGGCTGCT
2640

CTGCTGATCG GAGGCTTCGC AGGTCTCACC TCGACGGTGA TTTGCAGGTG GACACGCACT
2700

GGCACTAAAT CCACACTGCC CATCTCGGAG ACAGGCGGAG GAACTCCCGA GCTGAGATGC
2760

GGAAAGCACC AGGCCGTAGG GACCTCACCG CAGCGGGCCG CAGCTCAGGA CTCGGAGCAG
2820

GAGAGTGCTG GGATGGAAGG CCGGGATACT CACAGGCTGC CGAGAGCCCT CTGAGGGCAA
2880

AGTGGCAGGA CACTGCAGAA CAGCTTCATG TTCCCAAAT CACCGTACGA CTCTTTTCCA
2940

AACACAGGCA AATCGGAAAT CAGCAGGACG ACTGTTTTCC CAACACGGGT AAATCTAGTA
3000

CCATGTCGTA GTTACTCTCA GGCATGGATG AATAAATGTT ATAGCTGC
3048

- 68 -

WE CLAIM:

1. A method of screening for the presence of autoantibody to thyroid peroxidase in a sample comprising the steps of:
 - (a) providing the sample to be screened;
 - 5 (b) providing a thyroid peroxidase reagent comprising a substantially pure thyroid peroxidase epitopic peptide having an amino acid sequence selected from residue 456 to 933 of the Sequence of SEQ ID NO. 1 or an epitopic fragment thereof;
 - (c) providing means for detecting binding of the epitopic peptide to
10 autoantibody;
 - (d) contacting the autoantibody with the thyroid peroxidase reagent under conditions favorable for binding; and
 - (e) employing means for detecting the binding of the epitopic peptide to the autoantibody to screen for its presence.
- 15 2. The method of Claim 1, wherein the sample comprises biological fluid or tissue potentially containing an autoantibody.
3. The method of Claim 1, wherein the sequence of the epitopic fragment
20 consists essentially of from residue 517 to 630.
4. The method of Claim 1, wherein the sequence of the epitopic fragment consists essentially of from residue 633 to 933.
- 25 5. The method of Claim 1, wherein the sequence of the epitopic fragment consists essentially of from residue 592 to 613.
6. The method of Claim 2, wherein the sample comprises serum.

- 69 -

7. A method of screening for autoimmune thyroiditis in a patient comprising the steps of:

- (a) providing a biological tissue or fluid sample potentially containing an autoantibody from the patient;
- 5 (b) providing a thyroid peroxidase epitopic reagent comprising a substantially pure thyroid peroxidase epitopic peptide having an amino acid sequence from residue 517 to 630 or residue 633 to 933 of the sequence of SEQ ID NO. 1 or an epitopic fragment thereof;
- 10 (c) providing means for detecting binding of autoantibody to the epitopic peptide;
- (d) contacting the thyroid peroxidase epitopic reagent and autoantibody under conditions favorable for binding; and
- (e) employing means for detecting the binding of the autoantibody to the epitopic peptide to screen for the presence of autoimmune thyroiditis.

15

8. A method of treating Hashimoto's disease in a patient having a population of unbound autoantibody to a thyroid peroxidase epitope, comprising the steps of:

- 20 (a) selecting a substantially pure thyroid peroxidase epitopic peptide having binding equivalence to native thyroid peroxidase epitope;
- (b) providing the peptide in a biologically compatible form suitable for administration; and
- (c) administering the peptide to the patient in an amount sufficient to competitively bind substantially all the unbound autoantibody.

25

9. A method of treating Hashimoto's disease in a patient, wherein the patient has a population of thyroid peroxidase epitope and autoantibody thereto, comprising the steps of:

- 30 (a) selecting an autoantibody mimic capable of binding thyroid peroxidase native epitope without adversely affecting thyroid peroxidase function;
- (b) providing the autoantibody mimic in a biologically compatible form suitable for administration; and
- (c) administering the autoantibody mimic to the patient in an amount sufficient to bind substantially all of the thyroid peroxidase epitopes.

- 70 -

10. A method for inducing or stimulating an immune response to thyroid peroxidase in a population of cells comprising the steps of:

- (a) providing the population of cells;
- (b) providing a thyroid peroxidase reagent comprising a substantially pure thyroid peroxidase epitopic peptide consisting essentially of an amino acid sequence of from residue 465 to 933 of SEQ ID NO. 1 or an epitopic fragment thereof; and
- (c) treating the population of cells with the thyroid peroxidase reagent in an amount sufficient and for a time sufficient to induce or stimulate the immune response.

11. The method of Claim 10, wherein the step of providing the population of cells further comprises the step of harvesting the cells from a patient and the method further comprises the step of reintroducing at least a portion of the population after treatment with thyroid peroxidase reagent.

12. A method of stimulating the immune response to thyroid peroxidase in a recipient comprising the steps of:

- (a) providing a vaccine comprising an immunostimulatory reagent further comprising a substantially pure thyroid peroxidase epitopic peptide consisting essentially of an amino acid sequence of from residue 456 to 933 of SEQ ID NO. 1 or an epitopic fragment thereof, in a biologically compatible form suitable for administration; and
- (b) administering the vaccine in an amount sufficient to stimulate the response.

13. The method of Claim 12, wherein the sequence of the epitopic fragment consists essentially of from residue 517 to 630.

14. The method of Claim 12, wherein the sequence of the epitopic fragment consists essentially of from residue 633 to 933.

15. The method of Claim 12, wherein the sequence of the epitopic fragment consists essentially of from residue 592 to 613.

- 71 -

16. The method of Claim 12, wherein the vaccine further comprises an adjuvant.

17. A vaccine for inducing an immune response to thyroid peroxidase, the
5 vaccine comprising an immunostimulatory reagent further comprising a substantially pure thyroid peroxidase epitopic peptide consisting essentially of a sequence of amino acids of from residue 456 to 933 of SEQ ID NO. 1 or an epitopic fragment thereof.

18. The vaccine of Claim 17, wherein the peptide is obtained from a source
10 selected from the group consisting essentially of recombinant protein, synthetic peptides and native thyroid peroxidase.

19. The vaccine of Claim 17, wherein the sequence of the epitopic fragment
15 consists essentially of from residue 517 to 630.

20. The vaccine of Claim 17, wherein the sequence of the epitopic fragment consists essentially of from residue 633 to 933.

21. The vaccine of Claim 17, wherein the sequence of the epitopic fragment
20 consists essentially of from residue 592 to 613.

22. The vaccine of Claim 17, wherein the vaccine further comprises an adjuvant.

23. The vaccine of Claim 17, wherein the vaccine is for Hashimoto's
25 disease.

24. The vaccine of Claim 17, wherein the vaccine is for thyroid cancer.

25. A substantially pure thyroid peroxidase epitopic peptide consisting
30 essentially of an amino acid sequence of from residue 456 to 933 of SEQ ID NO. 1 or an epitopic fragment thereof.

26. The sequence of Claim 25, wherein the sequence of the epitopic
35 fragment consists essentially of from residue 517 to 630.

- 72 -

27. The sequence of Claim 25, wherein the sequence of the epitopic fragment consists essentially of from residue 633 to 933.

28. The sequence of Claim 25, wherein the sequence of the epitopic
5 fragment consists essentially of from residue 592 to 613.

29. The sequence of Claim 25, wherein the peptide is obtained from a source selected from the group consisting essentially of recombinant protein, synthetic peptides and native thyroid peroxidase.

10

30. A nucleic acid consisting essentially of a DNA or RNA sequence coding for the amino acid sequence or epitopic fragment thereof of Claim 25.

31. A nucleic acid consisting essentially of a DNA or RNA sequence coding
15 for the amino acid sequence or epitopic fragment thereof of Claim 26.

32. A nucleic acid consisting essentially of a DNA or RNA sequence coding for the amino acid sequence or epitopic fragment thereof of Claim 27.

20 33. A nucleic acid consisting essentially of a DNA or RNA sequence coding for the amino acid sequence or epitopic fragment thereof of Claim 28.

34. A nucleic acid having a sequence complementary to the sequence of Claim 29.

25

35. A nucleic acid having a sequence complementary to the sequence of Claim 31.

36. A nucleic acid having a sequence complementary to the sequence of
30 Claim 32.

37. A nucleic acid having a sequence complementary to the sequence of Claim 33.

38. A kit for assaying for autoimmune thyroiditis comprising:
- 5 (a) a substantially pure thyroid peroxidase epitopic peptide which specifically binds to thyroid peroxidase autoantibody, the peptide having a sequence consisting essentially of an amino acid sequence of from residue 456 to 933 of SEQ ID NO. 1 or an epitopic fragment thereof;
- (b) reagent means for detecting the binding of the autoantibody to the epitope; and
- 10 (c) the epitopic peptide and reagent means each being present in amounts effective to perform the immunoassay.
39. The kit of Claim 38, wherein the sequence of the epitopic fragment consists essentially of from residue 517 to 630.
- 15 40. The kit of Claim 38, wherein the sequence of the epitopic fragment consists essentially of from residue 633 to 933.
41. The kit of Claim 38, wherein the sequence of the epitopic fragment consists essentially of from residue 592 to 613.
- 20 42. A method of screening for the presence of Hashimoto's disease in a sample comprising the steps of:
- (a) providing the sample to be screened;
- (b) providing a thyroid peroxidase reagent comprising a substantially pure
25 thyroid peroxidase epitopic peptide having an amino acid sequence consisting essentially of from residue 456 to 933 of SEQ ID NO. 1 or an epitopic fragment thereof;
- (c) providing means for detecting binding of the epitopic peptide to autoantibody;
- 30 (d) contacting the autoantibody with the thyroid peroxidase reagent under conditions favorable for binding; and
- (e) employing means for detecting the binding of the epitopic peptide to the autoantibody.

- 74 -

43. The method of Claim 42, wherein the sample comprises biological fluid or tissue potentially containing an autoantibody.

44. The method of Claim 42, wherein the sequence of the epitopic fragment
5 consists essentially of from residue 592 to 613.

45. The method of Claim 42, wherein the sequence of the epitopic fragment consists essentially of from residue 633 to 933.

10 46. A method for treating autoimmune thyroidites in a patient having blood comprising serum having autoantibody specific for thyroid peroxidase, comprising the steps of:

- a) removing a portion of blood comprising serum having autoantibody from the patient;
- 15 b) providing a thyroid peroxidase epitopic reagent comprising a substantially pure thyroid peroxidase epitopic peptide having an amino acid sequence selected from residue 456 to 933 of the Sequence of SEQ ID NO. 1 or an epitopic fragment thereof;
- c) 20 contacting the thyroid peroxidase epitopic reagent with the portion of serum having autoantibody under conditions favorable for binding; and
- d) reintroducing the portion of serum to the patient.




FIG. 1A.






FIG. 1B.

2/20

Figure 2



3 / 2 0

Fig. 3.

SUBSTITUTE SHEET

4 / 20




FIG. 4

5/20


Figure 5


TPO-Maltose Binding Protein Fusion Products



Mol Wt. approx. 42 Kd

6 / 20


Fi . Fi .



Rabbit anti-MBP **Patient 1** **Patient 2**

Hi Lo Hi Lo

8/20

Figure 8

SUBSTITUTE SHEET

9/20

QSA	QMRP	Q87	Q96	Q97	Q98	Q99	Q100	Q101	Q102	Q103	Q104	Q105	Q106	Q107	Q108	Q109	Q110	Q111	Q112	Q113	Q114	Q115	Q116	Q117	Q118	Q119	Q120	Q121	Q122	Q123	Q124	Q125	Q126	Q127	Q128	Q129	Q130	Q131	Q132	Q133	Q134	Q135	Q136	Q137	Q138	Q139	Q140	Q141	Q142	Q143	Q144	Q145	Q146	Q147	Q148	Q149	Q150	Q151	Q152	Q153	Q154	Q155	Q156	Q157	Q158	Q159	Q160	Q161	Q162	Q163	Q164	Q165	Q166	Q167	Q168	Q169	Q170	Q171	Q172	Q173	Q174	Q175	Q176	Q177	Q178	Q179	Q180	Q181	Q182	Q183	Q184	Q185	Q186	Q187	Q188	Q189	Q190	Q191	Q192	Q193	Q194	Q195	Q196	Q197	Q198	Q199	Q200	Q201	Q202	Q203	Q204	Q205	Q206	Q207	Q208	Q209	Q210	Q211	Q212	Q213	Q214	Q215	Q216	Q217	Q218	Q219	Q220	Q221	Q222	Q223	Q224	Q225	Q226	Q227	Q228	Q229	Q230	Q231	Q232	Q233	Q234	Q235	Q236	Q237	Q238	Q239	Q240	Q241	Q242	Q243	Q244	Q245	Q246	Q247	Q248	Q249	Q250	Q251	Q252	Q253	Q254	Q255	Q256	Q257	Q258	Q259	Q260	Q261	Q262	Q263	Q264	Q265	Q266	Q267	Q268	Q269	Q270	Q271	Q272	Q273	Q274	Q275	Q276	Q277	Q278	Q279	Q280	Q281	Q282	Q283	Q284	Q285	Q286	Q287	Q288	Q289	Q290	Q291	Q292	Q293	Q294	Q295	Q296	Q297	Q298	Q299	Q300	Q301	Q302	Q303	Q304	Q305	Q306	Q307	Q308	Q309	Q310	Q311	Q312	Q313	Q314	Q315	Q316	Q317	Q318	Q319	Q320	Q321	Q322	Q323	Q324	Q325	Q326	Q327	Q328	Q329	Q330	Q331	Q332	Q333	Q334	Q335	Q336	Q337	Q338	Q339	Q340	Q341	Q342	Q343	Q344	Q345	Q346	Q347	Q348	Q349	Q350	Q351	Q352	Q353	Q354	Q355	Q356	Q357	Q358	Q359	Q360	Q361	Q362	Q363	Q364	Q365	Q366	Q367	Q368	Q369	Q370	Q371	Q372	Q373	Q374	Q375	Q376	Q377	Q378	Q379	Q380	Q381	Q382	Q383	Q384	Q385	Q386	Q387	Q388	Q389	Q390	Q391	Q392	Q393	Q394	Q395	Q396	Q397	Q398	Q399	Q400	Q401	Q402	Q403	Q404	Q405	Q406	Q407	Q408	Q409	Q410	Q411	Q412	Q413	Q414	Q415	Q416	Q417	Q418	Q419	Q420	Q421	Q422	Q423	Q424	Q425	Q426	Q427	Q428	Q429	Q430	Q431	Q432	Q433	Q434	Q435	Q436	Q437	Q438	Q439	Q440	Q441	Q442	Q443	Q444	Q445	Q446	Q447	Q448	Q449	Q450	Q451	Q452	Q453	Q454	Q455	Q456	Q457	Q458	Q459	Q460	Q461	Q462	Q463	Q464	Q465	Q466	Q467	Q468	Q469	Q470	Q471	Q472	Q473	Q474	Q475	Q476	Q477	Q478	Q479	Q480	Q481	Q482	Q483	Q484	Q485	Q486	Q487	Q488	Q489	Q490	Q491	Q492	Q493	Q494	Q495	Q496	Q497	Q498	Q499	Q500	Q501	Q502	Q503	Q504	Q505	Q506	Q507	Q508	Q509	Q510	Q511	Q512	Q513	Q514	Q515	Q516	Q517	Q518	Q519	Q520	Q521	Q522	Q523	Q524	Q525	Q526	Q527	Q528	Q529	Q530	Q531	Q532	Q533	Q534	Q535	Q536	Q537	Q538	Q539	Q540	Q541	Q542	Q543	Q544	Q545	Q546	Q547	Q548	Q549	Q550	Q551	Q552	Q553	Q554	Q555	Q556	Q557	Q558	Q559	Q560	Q561	Q562	Q563	Q564	Q565	Q566	Q567	Q568	Q569	Q570	Q571	Q572	Q573	Q574	Q575	Q576	Q577	Q578	Q579	Q580	Q581	Q582	Q583	Q584	Q585	Q586	Q587	Q588	Q589	Q590	Q591	Q592	Q593	Q594	Q595	Q596	Q597	Q598	Q599	Q600	Q601	Q602	Q603	Q604	Q605	Q606	Q607	Q608	Q609	Q610	Q611	Q612	Q613	Q614	Q615	Q616	Q617	Q618	Q619	Q620	Q621	Q622	Q623	Q624	Q625	Q626	Q627	Q628	Q629	Q630	Q631	Q632	Q633	Q634	Q635	Q636	Q637	Q638	Q639	Q640	Q641	Q642	Q643	Q644	Q645	Q646	Q647	Q648	Q649	Q650	Q651	Q652	Q653	Q654	Q655	Q656	Q657	Q658	Q659	Q660	Q661	Q662	Q663	Q664	Q665	Q666	Q667	Q668	Q669	Q670	Q671	Q672	Q673	Q674	Q675	Q676	Q677	Q678	Q679	Q680	Q681	Q682	Q683	Q684	Q685	Q686	Q687	Q688	Q689	Q690	Q691	Q692	Q693	Q694	Q695	Q696	Q697	Q698	Q699	Q700	Q701	Q702	Q703	Q704	Q705	Q706	Q707	Q708	Q709	Q710	Q711	Q712	Q713	Q714	Q715	Q716	Q717	Q718	Q719	Q720	Q721	Q722	Q723	Q724	Q725	Q726	Q727	Q728	Q729	Q730	Q731	Q732	Q733	Q734	Q735	Q736	Q737	Q738	Q739	Q740	Q741	Q742	Q743	Q744	Q745	Q746	Q747	Q748	Q749	Q750	Q751	Q752	Q753	Q754	Q755	Q756	Q757	Q758	Q759	Q760	Q761	Q762	Q763	Q764	Q765	Q766	Q767	Q768	Q769	Q770	Q771	Q772	Q773	Q774	Q775	Q776	Q777	Q778	Q779	Q780	Q781	Q782	Q783	Q784	Q785	Q786	Q787	Q788	Q789	Q790	Q791	Q792	Q793	Q794	Q795	Q796	Q797	Q798	Q799	Q800	Q801	Q802	Q803	Q804	Q805	Q806	Q807	Q808	Q809	Q810	Q811	Q812	Q813	Q814	Q815	Q816	Q817	Q818	Q819	Q820	Q821	Q822	Q823	Q824	Q825	Q826	Q827	Q828	Q829	Q830	Q831	Q832	Q833	Q834	Q835	Q836	Q837	Q838	Q839	Q840	Q841	Q842	Q843	Q844	Q845	Q846	Q847	Q848	Q849	Q850	Q851	Q852	Q853	Q854	Q855	Q856	Q857	Q858	Q859	Q860	Q861	Q862	Q863	Q864	Q865	Q866	Q867	Q868	Q869	Q870	Q871	Q872	Q873	Q874	Q875	Q876	Q877	Q878	Q879	Q880	Q881	Q882	Q883	Q884	Q885	Q886	Q887	Q888	Q889	Q890	Q891	Q892	Q893	Q894	Q895	Q896	Q897	Q898	Q899	Q900	Q901	Q902	Q903	Q904	Q905	Q906	Q907	Q908	Q909	Q910	Q911	Q912	Q913	Q914	Q915	Q916	Q917	Q918	Q919	Q920	Q921	Q922	Q923	Q924	Q925	Q926	Q927	Q928	Q929	Q930	Q931	Q932	Q933	Q934	Q935	Q936	Q937	Q938	Q939	Q940	Q941	Q942	Q943	Q944	Q945	Q946	Q947	Q948	Q949	Q950	Q951	Q952	Q953	Q954	Q955	Q956	Q957	Q958	Q959	Q960	Q961	Q962	Q963	Q964	Q965	Q966	Q967	Q968	Q969	Q970	Q971	Q972	Q973	Q974	Q975	Q976	Q977	Q978	Q979	Q980	Q981	Q982	Q983	Q984	Q985	Q986	Q987	Q988	Q989	Q990	Q991	Q992	Q993	Q994	Q995	Q996	Q997	Q998	Q999	Q1000	Q1001	Q1002	Q1003	Q1004	Q1005	Q1006	Q1007	Q1008	Q1009	Q1010	Q1011	Q1012	Q1013	Q1014	Q1015	Q1016	Q1017	Q1018	Q1019	Q1020	Q1021	Q1022	Q1023	Q1024	Q1025	Q1026	Q1027	Q1028	Q1029	Q1030	Q1031	Q1032	Q1033	Q1034	Q1035	Q1036	Q1037	Q1038	Q1039	Q1040	Q1041	Q1042	Q1043	Q1044	Q1045	Q1046	Q1047	Q1048	Q1049	Q1050	Q1051	Q1052	Q1053	Q1054	Q1055	Q1056	Q1057	Q1058	Q1059	Q1060	Q1061	Q1062	Q1063	Q1064	Q1065	Q1066	Q1067	Q1068	Q1069	Q1070	Q1071	Q1072	Q1073	Q1074	Q1075	Q1076	Q1077	Q1078	Q1079	Q1080	Q1081	Q1082	Q1083	Q1084	Q1085	Q1086	Q1087	Q1088	Q1089	Q1090	Q1091	Q1092	Q1093	Q1094	Q1095	Q1096	Q1097	Q1098	Q1099	Q1100	Q1101	Q1102	Q1103	Q1104	Q1105	Q1106	Q1107	Q1108	Q1109	Q1110	Q1111	Q1112	Q1113	Q1114	Q1115	Q1116	Q1117	Q1118	Q1119	Q1120	Q1121	Q1122	Q1123	Q1124	Q1125	Q1126	Q1127	Q1128	Q1129	Q1130	Q1131	Q1132	Q1133	Q1134	Q1135	Q1136	Q1137	Q1138	Q1139	Q1140	Q1141	Q1142	Q1143	Q1144	Q1145	Q1146	Q1147	Q1148	Q1149	Q1150	Q1151	Q1152	Q1153	Q1154	Q1155	Q1156	Q1157	Q1158	Q1159	Q1160	Q1161	Q1162	Q1163	Q1164	Q1165	Q1166	Q1167	Q1168	Q1169	Q1170	Q1171	Q1172	Q1173	Q1174	Q1175	Q1176	Q1177	Q1178	Q1179	Q1180	Q1181	Q1182	Q1183	Q1184	Q1185	Q1186	Q1187	Q1188	Q1189	Q1190	Q1191	Q1192	Q1193	Q1194	Q1195	Q1196	Q1197	Q1198	Q1199	Q1200	Q1201	Q1202	Q1203	Q1204	Q1205	Q1206	Q1207	Q1208	Q1209	Q1210	Q1211	Q1212	Q1213	Q1214	Q1215	Q1216	Q1217	Q1218	Q1219	Q1220	Q1221	Q1222	Q1223	Q1224	Q1225	Q1226	Q1227	Q1228	Q1229	Q1230	Q1231	Q1232	Q1233	Q1234	Q1235	Q1236	Q1237	Q1238	Q1239	Q1240	Q1241	Q1242	Q1243	Q1244	Q1245	Q1246	Q1247	Q1248	Q1249	Q1250	Q1251	Q1252	Q1253	Q1254	Q1255	Q1256	Q1257	Q1258	Q1259	Q1260	Q1261	Q1262	Q1263	Q1264	Q1265	Q1266	Q1267	Q1268	Q1269	Q1270	Q1271	Q1272	Q1273	Q1274	Q1275	Q1276	Q1277	Q1278	Q1279	Q1280	Q1281	Q1282	Q1283	Q1284	Q1285	Q1286	Q1287	Q1288	Q1289	Q1290	Q1291	Q1292	Q1293	Q1294	Q1295	Q1296	Q1297	Q1298	Q1299	Q1300	Q1301	Q1302	Q1303	Q1304	Q1305	Q1306	Q1307	Q1308	Q1309	Q1310	Q1311	Q1312	Q1313	Q1314	Q1315	Q1316	Q1317	Q1318	Q1319	Q1320	Q1321	Q1322	Q1323	Q1324	Q1325	Q1326	Q1327	Q1328	Q1329	Q1330	Q1331	Q1332	Q1333	Q1334	Q1335	Q1336	Q1337	Q1338	Q1339	Q1340	Q1341	Q1342	Q1343	Q1344	Q1345	Q1346	Q1347	Q1348	Q1349	Q1350	Q1351	Q1352	Q1353	Q1354	Q1355	Q1356	Q1357	Q1358	Q1359	Q1360	Q1361	Q1362	Q1363	Q1364	Q1365	Q1366	Q1367	Q1368	Q1369	Q1370	Q1371	Q1372	Q1373	Q1374	Q1375	Q1376	Q1377	Q1378	Q1379	Q1380	Q1381	Q1382	Q1383	Q1384	Q1385	Q1386	Q1387	Q1388	Q1389	Q1390	Q1391	Q1392	Q1393	Q1394	Q1395	Q1396	Q1397	Q1398	Q1399	Q1400	Q1401	Q1402	Q1403	Q1404	Q1405
-----	------	-----	-----	-----	-----	-----	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------

Patient A Patient B Patient C Protein Stain
A B C D A B C D A B C D A B C D

kDa

198

120

88


70

56

38

26

A - MBP-TPO (AA 632-933)
B - MBP-TPO (AA 456-631)
C - Human Thyroid Membranes
D - MBP-LacZ α



SUBSTITUTE SHEET

FIG. 10.

FLP A B C D E F G H I J K L

MAC

kDa


120—
88—
70—
56—
38—
26—

SUBSTITUTE SHEET



Fig. 11.

12/20



Figure 12



13/20

Figure 13A


14/20

Figure 13B**Patient 97**

SUBSTITUTE SHEET

15/20

Figure 14








FIG. 15.


17/20

Figure 16







Fi 17 A.



Fi 17 B.

Figure 18

20/20

Figure 19

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/03837

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : Please See Extra Sheet.

US CL : 530/326, 395, 854; 435/7.4, 7.92, 975; 436/811

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/326, 395, 854; 435/7.4, 7.92, 975; 436/811

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
MEDLINE, APS, DERWENT WORLD PATENT INDEX, PIR 33, SWISS-PROT 23, A-GENESEQ 8

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, Volume 68, No. 6, issued 1989, Ludgate et al, "Antibodies to Human Thyroid Peroxidase in Autoimmune Thyroid Disease: Studies with a Cloned Recombinant Complementary Deoxyribonucleic Acid Epitope", pages 1091-1096, see entire document.	<u>1,2,25,29, 41,42</u> 3-7, 26-28, 43-44
X Y	WO, A, 91/02061 (Rapaport) 21 February 1991, see entire document, particularly Claims 9-10 and 21-22, and pages 8, 32-35, and 57-63.	<u>1-2,37"B", 41-42</u> 3-7, 38-40, 43-44

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be part of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*&*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search
09 JULY 1993

Date of mailing of the international search report
14 JUL 1993

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

JAMES L. GRUN, PH.D.

Facsimile No. NOT APPLICABLE

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/03837

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KLEIN, "NATURAL HISTORY OF THE MAJOR HISTOCOMPATIBILITY COMPLEX" published 1986 by John Wiley and Sons (N.Y.), see page 235.	6
X	JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, Volume 73, No. 4, issued October 1991, Libert et al, "Thyroperoxidase, but not the Thyrotropin Receptor, Contains Sequential Epitopes Recognized by Autoantibodies in Recombinant Peptides Expressed in the pUEX Vector", pages 857-860, see entire document, especially page 859, Figure 1.	<u>25, 29</u>
Y		3-5, 7, 26-28, 38-40, 43-44
X	CLIN. EXP. IMMUNOL., Volume 87, issued January 1992, Zanelli et al, "Use of Recombinant Epitopes to Study the Heterogeneous Nature of the Autoantibodies Against Thyroid Peroxidase in Autoimmune Thyroid Disease", pages 80-86, see entire document, especially page 84, Col 2.	<u>25, 29</u>
Y		3-5, 7, 26-28, 38-40, 43-44
Y	PROC. NATL. ACAD. SCI. USA, Volume 84, issued August 1987, Kimura et al, "Human Thyroid Peroxidase: Complete cDNA and Protein Sequence, Chromosome Mapping, and Identification of Two Alternately Spliced mRNAs", pages 5555-5559, see page 5557, Figure 2.	3-5, 7, 26-28, 38-40, 43-44
Y	JOURNAL OF IMMUNOLOGICAL METHODS, Volume 102, issued 1987, Geysen et al, "Strategies for Epitope Analysis Using Peptide Synthesis", pages 259-274, see entire document.	5, 28, 40, 43
Y	PHARMACIA P-L BIOCHEMICALS, "MOLECULAR AND CELL BIOLOGY CATALOGUE", published 1992 by Pharmacia P-L Biochemicals (Milwaukee), see pages 144-160.	3-4, 7, 26-27, 38-39, 44

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/03837

A. CLASSIFICATION OF SUBJECT MATTER: IPC (5):

A61K 37/50; C07K 3/04, 3/02, 7/10, 13/00; C12Q 1/28; G01N 33/564, 33/573

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

I. Claims 1-7, 25-29, and 37"B"-44, drawn to antigenic peptides of thyroid peroxidase and their use in a method and kit for the detection of anti-thyroid peroxidase autoantibodies classified in Class C 07 K, Subclass 13/00, Class C 12 Q, subclass 1/28, and Class G 01 N, Subclasses 33/564 and 33/573.

II. Claims 8, 10-24, and 45, drawn to therapeutic uses of thyroid peroxidase peptides classified in Class A 61 K, Subclass 37/50.

III. Claim 9 drawn to the therapeutic use of an antibody classified in Class A 61 K, Subclass 39/395.

IV. Claims 30-37"A" drawn to nucleic acids encoding thyroid peroxidase amino acid sequences classified in Class C 07 H, Subclass 15/12 or 17/00.

The inventions of Groups II-IV are not so linked as to form a single general inventive concept with each other or with the Main Invention of Group I. Groups II-IV share no special technical feature with each other or with the Main Invention.

Group II is drawn to the in vivo therapeutic uses of thyroid peroxidase peptides which are unrelated in design or performance to the in vitro assay for the detection of anti-thyroid peroxidase antibodies of the Main Invention. Thus the inventions are alternative methods, i.e. therapy or a diagnostic assay, using thyroid peroxidase peptides and share no special technical feature.

Group III is drawn to the in vivo therapeutic use of anti-thyroid peroxidase antibodies and is unrelated in structure, design, and performance to either the Main Invention or the method of Group II, thus, sharing no special technical feature.

Group IV is drawn to compositions which are structurally unrelated to the peptides or antibodies of the Main Invention and Groups II-III, thus sharing no special technical feature in common with the other inventions.